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Abstract
Background: Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the ‘preclinical’ stage
(pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive
impairment. Developing and judiciously administering such therapies will require biomarker panels to identify early AD
pathology, classify disease stage, monitor pathological progression, and predict cognitive decline. To discover such
biomarkers, we measured AD-associated changes in the cerebrospinal fluid (CSF) proteome.
Methods and Findings: CSF samples from individuals with mild AD (Clinical Dementia Rating [CDR] 1) (n=24) and cognitively
normalcontrols(CDR 0) (n=24)were subjectedto two-dimensional difference-in-gel electrophoresis. Within119differentially-
abundant gel features,mass spectrometry(LC-MS/MS) identified 47 proteins. Forvalidation, eleven proteins were re-evaluated
by enzyme-linked immunosorbent assays (ELISA). Six of these assays (NrCAM, YKL-40, chromogranin A, carnosinase I,
transthyretin, cystatin C) distinguished CDR 1 and CDR 0 groups and were subsequently applied (with tau, p-tau181 and Ab42
ELISAs) to a larger independent cohort (n=292) that included individuals with very mild dementia (CDR 0.5). Receiver-
operating characteristic curve analyses using stepwise logistic regression yielded optimal biomarker combinations to
distinguish CDR 0 from CDR.0 (tau, YKL-40, NrCAM) and CDR 1 from CDR,1 (tau, chromogranin A, carnosinase I) with areas
under the curve of 0.90 (0.85–0.94 95% confidence interval [CI]) and 0.88 (0.81–0.94 CI), respectively.
Conclusions: Four novel CSF biomarkers for AD (NrCAM, YKL-40, chromogranin A, carnosinase I) can improve the diagnostic
accuracy of Ab42 and tau. Together, these six markers describe six clinicopathological stages from cognitive normalcy to
mild dementia, including stages defined by increased risk of cognitive decline. Such a panel might improve clinical trial
efficiency by guiding subject enrollment and monitoring disease progression. Further studies will be required to validate
this panel and evaluate its potential for distinguishing AD from other dementing conditions.
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Clinicopathological studies suggest that Alzheimer’s disease
(AD) pathology (amyloid plaque formation, followed by gliosis and
neurofibrillary tangle formation) begins 10–15 years before the
onset of very mild dementia [1,2]. This period of ‘preclinical AD’
could provide an opportunity for disease modifying therapies to
prevent or forestall the synaptic and neuronal losses associated
with cognitive impairment [3–5]. However, before such interven-
tions can be developed and judiciously administered, accurate
tools must be in place to diagnose and monitor the pathophys-
iological condition of individuals with preclinical AD and very
early stage AD dementia. Clinical examination cannot detect
preclinical disease or measure cellular and molecular changes
within the brain, and, in general, has limited accuracy when
diagnosing the very earliest symptomatic stages of AD. Therefore,
there is an urgent need to identify biomarkers that can do so.
Because its composition is rapidly and directly influenced by the
brain, the cerebrospinal fluid (CSF) proteome represents an
appealing source for such biomarkers.
Indeed, a few CSF proteins have already shown promise as
diagnostic biomarkers for clinical AD (dementia of the Alzheimer
type [DAT]) and even preclinical AD. Lower mean levels of CSF
Ab42 and higher mean levels of tau and phosphorylated tau can
distinguish groups with DAT from cognitively normal controls
[6,7]. Unfortunately, value ranges for each biomarker show
substantial overlap between groups.
Recently, using positron-emission tomography PET imaging
with Pittsburgh Compound B (PIB) to measure brain amyloid in
vivo, we and others have demonstrated that low CSF Ab42 can
serve as an indicator of amyloid deposition [8–13], and that CSF
tau levels correlate positively with in vivo brain amyloid load
[11,14]. Importantly, both of these associations are independent of
clinical diagnosis [8–11], though CSF tau does correlate with more
sensitive measures of cognition [14]. These findings suggest that
the overlap of biomarker values between clinical groups may, in
part, reflect ‘‘contamination’’ of control groups by cognitively
normal individuals exhibiting amyloid plaques and early neuro-
degeneration (preclinical AD), low CSF Ab42 and elevated CSF
tau. Supporting this notion, elevated ratios of tau/Ab42 and p-
tau181/Ab42 (consistent with the presence of amyloid plaques and
neurodegeneration) have been associated with increased risk of
converting from cognitive normalcy to mild cognitive impairment
or dementia [9,15], and with increased rate of cognitive decline
among those with very mild dementia [16]. Together, these
findings suggest that CSF biomarkers can describe neuropatho-
logical state and trajectory. They also suggest that a pathological
staging system based on biomarkers might be a favorable
alternative or adjunct to clinical staging for guiding treatment
decisions or designing clinical trials.
Beyond amyloid plaque formation, other features of AD
pathophysiology might also be exploited as therapeutic targets,
sources of diagnostic biomarkers, or measures of disease
progression. In addition to Ab42 and tau, many other candidate
AD biomarkers have been identified by either targeted or
unbiased proteomics screens [17–27]. Only a few of these studies
have tested large, well-characterized cohorts, however. Even
fewer have evaluated biomarkers for their ability to distinguish
the very early stages of AD pathophysiology. Thus, there remains
a critical need for validated AD biomarkers that can properly
categorize individuals by early pathological stage; such markers
may have potential for monitoring neuropathological decline
and, thereby, for evaluating response to disease-modifying
therapies.
The goal of this study, therefore, is to identify such CSF protein
biomarkers for AD using the unbiased proteomic technique of
two-dimensional difference-in-gel electrophoresis (2D-DIGE) cou-
pled with liquid chromatography and tandem mass spectrometry
(LC-MS/MS), and to evaluate them further in a larger
independent cohort using quantitative enzyme-linked immuno-
sorbent assays (ELISA). Our findings suggest that a small ensemble
of novel biomarkers may be able to distinguish several stages of
cognitive decline in early AD, and improve the ability of current
leading biomarkers tau and Ab42 to discriminate early symptom-
atic AD from cognitive normalcy.
Methods
Ethics Statement
The study protocols were approved by the institutional review
boards of the University of Washington, the Oregon Health and
Science University, the University of Pennsylvania, the University
of California San Diego, and Washington University. Written
informed consent was obtained from all participants at enrollment.
All aspects of this study were conducted according to the principles
expressed in the Declaration of Helsinki.
Participant Selection for Discovery Cohort
Participants (n=48), community-dwelling volunteers from
University of Washington [n=18], Oregon Health and Science
University [n=11], University of Pennsylvania [n=11], and
University of California San Diego [n=8], were 51–87 years of
age and in good general health, having no other neurological,
psychiatric, or major medical diagnoses that could contribute to
dementia, nor use of exclusionary medications (e.g. anticoagulants)
within 1–3 months of lumbar puncture (LP). Cognitive status was
evaluated based on criteria from the National Institute of
Neurological and Communicative Diseases and Stroke-Alzhei-
mer’s Disease and Related Disorders Association [28]. In the
morning after overnight fasting, CSF was obtained by LP,
collected and aliquoted in polypropylene tubes, and immediately
frozen at 280uC. Participants who were cognitively normal
(Clinical Dementia Rating [CDR] of 0 [n=24]) [29], or had mild
‘‘probable AD’’ (CDR 1) (n=24), were selected from a larger
group of 120 individuals on the basis of CSF Ab42 (relatively high
and low values, respectively), and, when possible, CSF tau
(relatively low and high values, respectively) to increase the
likelihood of CDR 1 participants having and CDR 0 participants
not having AD pathology. CSF Ab42 and tau levels for the
discovery cohort were all measured in a single laboratory using
well-established ELISA assays ([30] and Innotest, Innogenetics,
Ghent, Belgium). Although quantitative thresholds were not
defined prior to sample selection, the lowest CDR 0 value and
the highest CDR 1 value for CSF Ab42 in this ‘discovery cohort’
were 609 and 361 pg/mL, respectively; ranges for CSF tau were
141–461 pg/mL for CDR 0 and 215–1965 pg/mL for CDR 1.
Participant Selection for Validation Cohort
Participants (n=292), community-dwelling volunteers enrolled
at the Knight Alzheimer Disease Research Center at Washington
University (WU-ADRC), were $60 years of age and met the same
exclusion criteria as the discovery cohort. The study protocol was
approved by the Human Studies Committee at Washington
University, and written and verbal informed consent was obtained
from participants at enrollment. Cognitive status was determined
as with the discovery cohort. Participants who were cognitively
normal (CDR 0, n=198), very mildly demented (CDR 0.5, n=65)
or mildly demented (CDR 1, n=29) at the time of LP were
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CDR 0.5 participants met criteria for mild cognitive impairment
(MCI) and some showed even milder impairment, and could be
considered ‘‘pre-MCI’’ [31]. All CDR 1 individuals had received a
diagnosis of DAT (See Table 1 for demographic characteristics).
Apolipoprotein E (APOE) genotypes were determined by the WU-
ADRC Genetics Core. Fasted CSF (20–30 mL) was collected,
gently mixed, centrifuged, aliquoted and frozen at 280uCi n
polypropylene tubes [9].
Multi-Affinity Immunodepletion of CSF
A pooled CSF sample, containing an equivalent volume from
every ‘discovery’ cohort sample, was prepared as an internal
standard for 2D-DIGE to facilitate the matching of gel features,
and to allow normalization of the intensity of each gel feature
among different gels. To enrich for proteins of low-abundance
prior to 2D-DIGE, each CSF sample was depleted of six highly-
abundant proteins (albumin, IgG, IgA, haptoglobin, transferrin,
and a-1-antitrypsin) by immunoaffinity chromatography (Agilent
Technologies, Palo Alto, CA) according to the manufacturer’s
instructions and as described previously [32]. Depleted samples
were then concentrated using 10 kDa exclusion filters to retain
larger molecules. As a ‘benchmark’ of immunodepletion column
performance, an aliquot of reference CSF was depleted after every
group of seven experimental chromatographic depletions. Non-
depleted reference CSF, depleted CSF and the proteins that were
retained by the column were analyzed by 2D-DIGE as previously
described [32,33]; gel images obtained from all reference CSF
depletion analyses were similar (data not shown), indicating
consistent column performance over time.
2D-DIGE
2D-DIGE was performed as described previously [32,33].
Briefly, CDR 0 and CDR 1 samples were randomly paired. 50
micrograms of protein from each paired sample and from an
aliquot of the pooled CSF sample were labeled with one of three
N-hydroxysuccinimide cyanine dyes. The labeled proteins and 100
micrograms of unlabeled protein from each sample were mixed
and equilibrated with an immobilized pH gradient strip for
isoelectric focusing (first dimension), after which the strip was
treated with reducing and alkylating solutions prior to SDS-PAGE
(second dimension). Cy2, Cy3 and Cy5-labeled images were
acquired on a Typhoon 9400 scanner (GE Healthcare, United
Kingdom) at excitation/emission wavelengths of 488/520, 532/
580, and 633/670 nm, respectively.
Gel Image and Statistical Analysis
The comparative two-dimensional gel analysis was performed
using an established experimental design [34] in which the high
variation between gels is minimized by including a common,
labeled pooled sample in all gels. Intra-gel feature detection,
quantification and inter-gel matching and quantification were
performed using the Differential In-Gel Analysis (DIA) and
Biological Variation Analysis (BVA) modules of DeCyder software
v 6.5 (GE Healthcare), respectively, as described previously [32].
This process (DIA analysis) resulted in approximately 5,000 gel
features per gel image. In five gels, one sample contained
significant amounts of hemoglobin indicating possible blood
contamination. Therefore, all images from gels with these
hemoglobin-containing samples were removed from further
analysis. Remaining gel images were separated into three sets:
standard (pool of all samples), CDR 0 and CDR 1. The pooled
sample image with the largest number of well-resolved gel features
was chosen as a master image. Gel features in each remaining
pooled sample image were hand matched to gel features in the
master image. For each gel feature that was matched across .50%
of the gels (n=764), a Student’s t-test (a=0.05) was performed to
determine the statistical significance of CDR 0/CDR 1 ratios,
using the DeCyder EDA (Extended Data Analysis) module. To
maximize discovery rate and minimize type II error, no multiple
test correction was applied. The image intensity data for the
statistically significant gel features (n=119) were then subjected to
unsupervised hierarchical clustering (DeCyder EDA module).
Protein/Peptide Identification by LC-MS/MS
Gel features with significant intensity differences were targeted
by a robotic gel sampling system (ProPic; Genomics Solutions,
Ann Arbor, MI) and transferred into 96 well plates for in-gel
digestion with trypsin using a modification of a method [35]
described previously [33]. Aliquots of these digests were processed
for and analyzed by LC-MS/MS using a capillary LC (Eksigent,
Livermore CA) interfaced to a nano-LC-linear quadrupole ion
trap Fourier transform ion cyclotron resonance mass spectrometer
(nano-LC-FTMS) [36] QStar [37] or LTQ [36]. The tandem
spectra were searched against the National Center for Biotech-
nology Information non-redundant protein database NR (down-
loaded on 02-18-2007) using MASCOT, version 2.2.04 (Matrix
Sciences, London). The database searches were constrained by
allowing for trypsin cleavage (with up to two missed cleavage sites),
fixed modifications (carbamidomethylation of Cys residues) and
variable modifications (oxidation of Met residues and N-terminal
pyroglutamate formation). Protein identifications were considered
genuine if at least two peptides were matched with individual
MASCOT ion scores $40.
Using nano-LC-MS/MS, multiple proteins were identified in the
majority of individual gel features. The frequent observation of
multiple proteins in single gel features was attributed to the
sensitivity and greater peptide coverage that can be achieved with
nano-LC-MS methods as compared to, for example, MALDI-MS
analysis of peptides from gel features. Assignment of the major
protein(s) from each gel feature was achieved using quantitative
proteomics from spectra counting [38]. The detection of multiple
proteinswithinsinglegel featurescouldalsobeattributedtoartifacts
and technical issues associated with 2D gel electrophoresis: 1)
incomplete resolution of proteins by gel electrophoresis (due to
similar charge and size characteristics, excessive abundance of
Table 1. Demographic, clinical, genotype characteristics of
validation cohort.
Characteristic CDR 0 CDR 0.5 CDR 1
Number of Participants 198 65 29
Gender (% Female) 63% 54% 52%
APOE genotype, % e4 positive 35% 51% 59%
Mean MMSE score (SD) 28.9 (1.3) 26.3 (2.8) 22.3 (3.9)
Mean age at LP (SD), years 71.0 (7.3) 73.8 (6.8) 76.5 (6.2)
Mean CSF Ab42 (SD), pg/mL 605 (240) 446 (230) 351 (118)
Mean CSF tau (SD), pg/mL 304 (161) 539 (276) 552 (263)
Mean CSF p-tau181 (SD), pg/mL 55 (25) 85 (44) 77 (38)
Abbreviations: CDR, Clinical Dementia Rating; CDR 0, cognitively normal; CDR
0.5, very mild dementia; CDR 1 mild dementia; APOE, apolipoprotein E; MMSE,
Mini-Mental State Examination; LP, lumbar puncture; SD, standard deviation;
CSF, cerebrospinal fluid; Ab42, amyloid beta 42 peptide; p-tau181, tau
phosphorylated at threonine 181.
doi:10.1371/journal.pone.0016032.t001
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molecular weight associated with cyanine dye labeling, particularly
for lower molecular weight proteins; and 3) sample ‘carryover’
during robotic gel sampling or during nano-LC-MS/MS.
All relevant proteomics data are detailed in Table S1.
Enzyme Linked Immunosorbent Assays (ELISAs) and
Statistical Analyses
CSF samples were analyzed by ELISA in duplicate for Ab42,
total tau, and phospho-tau181 (Innotest, Innogenetics, Ghent,
Belgium) after one freeze-thaw cycle, and in triplicate for all other
ELISAs after two freeze-thaw cycles. Samples were evaluated
using commercially available ELISAs for NrCAM (R&D Systems
Inc., Minneapolis, MN), YKL-40 (Quidel Corporation, San
Diego, CA), apolipoprotein E (Medical and Biological Laborato-
ries Company, Ltd., Nagoya, Japan), clusterin/apolipoprotein J
(ALPCO Diagnostics, Salem, NH), pigment epithelium-derived
factor (PEDF)/serpin-F1 (Chemicon International Inc./ Millipore
Corporation, Billerica, MA), beta-2 microglobulin (ALPCO
Diagnostics), ceruloplasmin (Assaypro, St. Charles, MO), chromo-
granin A (ALPCO Diagnostics, low binding capacity manufactur-
ing protocol), transthyretin (Assaypro), and cystatin C (US
Biological, Swampscott, MA), according to manufacturer’s
instructions, with adjustments for the analysis of CSF. A sandwich
ELISA was developed for carnosinase I using goat anti-human
carnosinase I antibody (2 mg/mL, R&D Systems Inc.) for capture,
rabbit anti-human carnosinase I antibody (1 mg/mL, Sigma-
Aldrich Corporation, St. Louis, MO) for detection, goat anti-
rabbit:horseradish peroxidase (1:5000, Upstate Biologicals Inc./
Millipore Corporation) for reporting, and TMB (3,39,5,59-tetra-
methylbenzidine) Super Slow (Sigma-Aldrich Corporation) for
color development; recombinant carnosinase I (R&D Systems Inc.)
was used as standard.
Statistical analyses were performed using commercially avail-
able software: SAS 9.2 (SAS Institute Inc., Cary, NC) for Receiver
Operating Characteristic (ROC)/area under curve (AUC) calcu-
lations and logistic regression analyses, and SPSS 18 (SPSS Inc.,
Chicago, IL) for all other analyses.
Figure 1. Two-dimensional difference in gel electrophoresis (2D-DIGE) of cerebrospinal fluid immunodepleted of six high
abundance proteins. Representative 2D-DIGE (grayscale) image with labeled locations of 119 gel features that differed in intensity between CDR 0
and CDR 1 groups. Gel features are numbered 1 through 119, and relevant information about each is listed in Table 2 and in Table S1. Approximate
molecular weight (in kilodaltons [kDa]) is indicated along the right border; isoelectric point ranges from 3 (left) to 11(right) and is non-linear (not
shown). The large, intense, protein spots commonly attributed to transthyretin are boxed; a subset of the differentially abundant gel features in
which transthyretin was identified by mass spectrometry is circled.
doi:10.1371/journal.pone.0016032.g001
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Spot BVA GI number(s) Protein Change p value Protein
1 4709 31543193 hypothetical protein LOC146556 21.36 7.02E-04 1
2 5659 4502807 chromogranin B 21.31 1.18E-03 2
3 4683 4502101 annexin I 21.31 9.54E-04 3
4 4608 62089004 chromogranin B 21.24 6.49E-03
181387 cystatin C 4
134464 secretogranin-2 5
5 4297 4502807 chromogranin B 21.26 0.0157
6 4545 21.34 3.86E-03
7 4695 4502807 chromogranin B 21.27 0.0115
8 4044 4502807 chromogranin B 21.32 2.15E-03
9 1314 1621283 neuronal cell adhesion molecule (NrCAM) 21.22 0.0119 6
10 1320 1621283 neuronal cell adhesion molecule (NrCAM) 21.33 6.31E-04
11 1382 6651381 neuronal cell adhesion molecule (NrCAM) 21.28 9.53E-04
12 1383 6651381 neuronal cell adhesion molecule (NrCAM) 21.25 6.64E-03
13 4033 4502807 chromogranin B 21.21 0.0419
14 4191 4502807 chromogranin B 21.23 0.0107
15 4293 4502807 chromogranin B 21.33 4.64E-03
825635 calmodulin 7
16 4266 62089004 chromogranin B 21.22 0.0315
17 4615 21.22 0.0188
18 4677 21.3 9.63E-03
19 4906 5454032 S100 calcium binding protein A1 21.3 1.36E-04 8
62898141 prosaposin 9
627391 brain-associated small cell lung cancer antigen/NCAM-140/CD56 10
17136078 VGF nerve growth factor inducible precursor 11
20 5014 443295 transthyretin 21.3 2.10E-03 12
21 4884 224917 apolipoprotein CIII 21.34 9.78E-04 13
337760 prosaposin/cerebroside sulfate activator protein
22 3423 39654998 chain A, Hr1b Domain From Prk1 21.27 0.0133 14
32171249 prostaglandin H2 D-isomerase/beta trace 15
23 3470 17402888 neuronal pentraxin receptor 21.25 7.23E-03 16
114593356 extracellular superoxide dismutase (SOD3) 17
24 4954 34616 beta-2 microglobulin 21.3 4.15E-03 18
25 3436 32171249 prostaglandin H2 D-isomerase 21.22 0.0266
178775 proapolipoprotein 19
39654998 chain A, Hr1b Domain From Prk1
26 3714 21.27 0.03
27 4922 39654998 chain A, Hr1b Domain From Prk1 21.27 0.0194
28 3786 2072129 chromogranin A 21.38 8.96E-03 20
29 4076 7341255 brain acetylcholinesterase putative membrane anchor 21.25 0.0375 21
30 4111 62089004 chromogranin B 21.28 0.0206
31 4167 4502807 chromogranin B 21.29 0.0207
32 2652 28373309 gelsolin 21.23 0.0346 22
33 1313 6651381 neuronal cell adhesion molecule (NrCAM) 21.19 8.08E-03
34 1372 1620909 ceruloplasmin 21.19 9.00E-03 23
1483187 inter-alpha-trypsin inhibitor family heavy chain-related protein 24
31874098 hypothetical protein (NrCAM)
6651381 neuronal cell adhesion molecule (NrCAM)
35 1387 68534652 neuronal cell adhesion molecule (NrCAM) 21.29 8.16E-05
1620909 ceruloplasmin
Novel CSF Biomarkers for Early Alzheimer’s Disease
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36 4808 337760 prosaposin/cerebroside sulfate activator protein 21.22 0.0114
37 1319 68534652 neuronal cell adhesion molecule (NrCAM) 21.19 0.0198
1942284 ceruloplasmin
38 1386 6651381 neuronal cell adhesion molecule (NrCAM) 21.29 1.24E-03
39 1353 21706696 calsyntenin 1 21.22 0.0417 25
40 1329 1621283 neuronal cell adhesion molecule (NrCAM) 21.22 4.61E-03
41 2456 5802984 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 21.13 0.0449 26
42 2550 20178323 pigment epithelium-derived factor precursor (PEDF)/Serpin-F1/EPC-1 21.15 0.022 27
43 2125 21071039 carnosinase 1 21.21 0.0245 28
44 2131 21071039 carnosinase 1 21.19 0.049
45 2152 21071039 carnosinase 1 21.15 0.0366
46 5614 21071039 carnosinase 1 21.18 0.0109
47 2166 21071039 carnosinase 1 21.21 0.0122
48 2328 416180 man9-mannosidase/a1,2-mannosidase IA 21.16 0.0464 29
49 3360 21.15 0.045
50 3447 32171249 prostaglandin H2 D-isomerase/beta trace 21.19 0.0334
51 3546 1621283 neuronal cell adhesion molecule (NrCAM) 21.17 0.0368
32171249 prostaglandin H2 D-isomerase/beta trace
52 4745 443295 transthyretin 21.26 0.0181
53 3032 11056046 nectin-like molecule-1/SynCAM3/TSLL1 21.13 0.0472 30
54 3718 39654998 chain A, Hr1b Domain From Prk1 21.14 0.0455
32171249 prostaglandin H2 D-isomerase/beta trace
55 4902 14277770 apolipoprotein C-Ii 21.19 0.0495 31
337760 prosaposin/cerebroside sulfate activator protein
2072129 chromogranin A
56 3290 409725 carbonic anhydrase IV 21.14 0.0141 32
57 4379 17942890 transthyretin 21.15 0.0219
39654998 chain A, Hr1b Domain From Prk1
34999 cadherin 2 precursor 33
58 4388 32171249 prostaglandin H2 D-isomerase/beta trace 21.14 0.0218
39654998 chain A, Hr1b Domain From Prk1
443295 transthyretin
59 2192 21071039 carnosinase 1 21.34 6.56E-03
532198 angiotensinogen 34
5531817 secretogranin III 35
9665262 EGF-containing fibulin-like extracellular matrix protein 1/Fibulin-3 36
177933 alpha-1-antichymotrypsin 37
4504893 kininogen 1 38
36573 vitronectin 39
60 5336 443295 transthyretin 21.17 0.0301
61 3009 178855 apolipoprotein J/clusterin 21.26 0.0288 40
4557325 apolipoprotein E 41
62 3042 4557325/178853 apolipoprotein E 21.21 0.047
338305 apolipoprotein J/clusterin
63 3016 338305 apolipoprotein J/clusterin 21.32 6.69E-05
64 3050 4557325/178853 apolipoprotein E 21.24 5.19E-04
178855 apolipoprotein J/clusterin
65 3075 4557325/178853 apolipoprotein E 21.42 5.59E-06
178855 apolipoprotein J/clusterin
66 3038 4557325/178853 apolipoprotein E 21.41 2.84E-05
Table 2. Cont.
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178855 apolipoprotein J/clusterin
67 3301 178849 apolipoprotein E 21.4 1.29E-05
68 3182 4557325/178853 apolipoprotein E 21.41 3.43E-04
178855 apolipoprotein J/clusterin
69 2443 532198 angiotensinogen 21.2 6.85E-03
70 2493 4503009 carboxypeptidase E precursor 21.23 6.09E-03 42
71 5621 532198 angiotensinogen 21.17 0.0434
72 5624 532198 angiotensinogen 21.22 0.0147
73 5622 553181 angiotensinogen 21.17 0.04
74 5625 532198 angiotensinogen 21.16 0.0423
75 5627 21.22 0.0113
76 2849 4557325 apolipoprotein E 21.28 6.26E-03
77 5009 443295 transthyretin 21.24 0.0268
78 5033 443295 transthyretin 21.27 4.59E-03
79 5078 443295 transthyretin 21.2 0.0144
80 2958 4504067 aspartate aminotransferase 1 21.22 8.60E-03 43
81 3657 32171249 prostaglandin H2 D-isomerase/beta trace 21.22 3.07E-03
82 3867 21.28 0.0437
83 3176 4557325 apolipoprotein E 21.63 3.03E-04
84 3228 4557325 apolipoprotein E 21.4 1.39E-03
443295 transthyretin
85 3074 4557325/178853 apolipoprotein E 22.36 4.41E-09
86 5647 4557325 apolipoprotein E 22.35 2.92E-07
87 3224 4557325/178853 apolipoprotein E 22.13 6.36E-07
443295 transthyretin
88 3126 4557325/178853 apolipoprotein E 21.93 7.55E-06
89 5297 21.44 0.0473
90 3083 4557325 apolipoprotein E 21.7 2.82E-05
91 2218 112911 alpha-2-macroglobulin 1.22 0.0282 44
92 2226 6573461 apolipoprotein H 1.27 0.0305 45
93 2252 112911 alpha-2-macroglobulin 1.26 0.0267
4557327 apolipoprotein H
94 3255 1.24 0.0315
95 3630 178775 proapolipoprotein 1.24 0.0287
32171249 prostaglandin H2 D-isomerase/beta trace
39654998 chain A, Hr1b Domain From Prk1
96 2229 177933 alpha-1-antichymotrypsin 1.42 3.09E-03
97 2235 177933 alpha-1-antichymotrypsin 1.35 0.0388
98 2261 177933 alpha-1-antichymotrypsin 1.3 6.04E-03
99 2262 177933 alpha-1-antichymotrypsin 1.25 0.0294
100 2220 1.29 0.0158
101 3084 1.16 0.0211
102 3508 32171249 prostaglandin H2 D-isomerase/beta trace 1.22 9.21E-03
103 2825 23512215 chitinase 3-like 1/YKL-40/HC-gp39 1.41 0.0167 46
104 2863 4557018 chitinase 3-like 1/YKL-40/HC-gp39 1.5 0.0144
105 2846 29726259 chitinase 3-like 1/YKL-40/HC-gp39 1.46 7.88E-03
106 2843 23512215 chitinase 3-like 1/YKL-40/HC-gp39 1.32 0.0241
107 3030 4557325 apolipoprotein E 2.46 3.70E-05
108 3152 4557325/178853 apolipoprotein E 2.39 8.73E-07
109 3203 178853 apolipoprotein E 3.23 3.13E-07
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cohort (one sample was unavailable for re-evaluation, n=47) were
performed using unpaired t-test. For the ‘validation’ cohort (n=292),
correlations with age and gender were evaluated using the Spearman
rho correlation coefficient (a=0.05). Chi-square analyses were
performed to evaluate need for adjustment for observed correlations.
Comparisons between the three CDR groups were performed using
one-way analysis of variance (ANOVA), with Bonferroni and LSD
post-hoc tests for pair-wise group comparisons, with the following
exceptions: one-way ANOVA with Welch’s correction was applied
for markers (transthyretin) demonstrating unequal variances (Levene
,.05); markers correlating with age (tau, p-tau181, Ab42, YKL-40)
were evaluated by analysis of covariance (ANCOVA) adjusting for
age, followed by Bonferroni and LSD post-hoc tests. Multiple post-
hoc tests were applied in recognition of their different levels of
stringency (Bonferroni . LSD), and their non-uniform popularity
among statisticians.For CDR0 vs.0co m pa ri son san dCD R1v s,1
comparisons, unpaired t-test was used; Welch’s correction for unequal
variances was applied for YKL-40, p-tau181, tau, and Ab42. For each
biomarker measured in the larger ‘validation’ cohort, the ROC curve
and the AUC were calculated for predicting CDR 0 versus CDR.0.
A stepwise logistic regression analysis was used to identify an optimal
combination of these biomarkers for this data set. These analyses were
repeated for CDR 1 vs CDR,1.
Results
Sample Processing and 2D-DIGE Analysis
To identify new candidate biomarkers for AD, we utilized an
unbiased proteomics approach, 2D-DIGE LC-MS/MS [32,33],
to compare the relative concentrations of CSF proteins in
individuals with mild ‘‘probable AD’’ (CDR 1, n=24) to those in
individuals with normal cognition (CDR 0, n=24). The two
clinical groups were selected on the basis of relative biomarker
values for CSF Ab42 and tau (see Methods), and differed
somewhat with respect to age at LP and gender (CDR 0:
64.868.8 yrs, 38% female; CDR 1: 72.8 yrs 67.9 yrs, 54%
female). Five samples showed evidence of blood contamination by
2D-DIGE; the five gels containing these samples were excluded
from subsequent image analyses. The remaining individual
sample images (n=38, from 19 gels) were aligned using the
BVA module (described under Methods).
Among the 764 gel features that were present in .50% of the
gels, 119 were found to have significant intensity differences
between CDR 0 and CDR 1 groups (Student’s t-test [a=0.05])
(Figure 1). The image intensity data for these 119 gel features were
subjected to unsupervised hierarchical clustering (EDA module,
DeCyder software) and the gel features themselves were analyzed
for protein composition.
Protein Identification by LC-MS/MS
LC-MS/MS identified single dominant proteins in 78 of the 119 gel
features (Table 2). In 29 gel features, our analyses identified two or
more co-dominant proteins. The 12 remaining gel features were not
annotated from the nano-LC-MS/MSdata.Among the characterized
gel features, there was considerable redundancy in protein identifica-
tions, with some proteins appearing in multiple gel features. Such
‘redundant’ gel features, likely representing a modified form or variant
of the same ‘parent’ protein, generally migrated with some proximity
on 2D-gel electrophoresis (Figure 1). Forty-seven unique proteins were
identified (Table 2). Thirteen of these unique proteins had been
identified in our previous studies [32,33] (including chromogranin B,
cystatin C, prostaglandin H2 D-isomerase/beta trace, neuronal
pentraxin receptor, gelsolin, beta-2 microglobulin, carnosinase I,
angiotensinogen, apolipoprotein H, secretogranin III, alpha-1-antic-
hymotrypsin, chitinase 3-like 1/YKL-40, and kininogen I) and others
Spot BVA GI number(s) Protein Change p value Protein
110 3185 4557325/178853 apolipoprotein E 1.9 9.72E-04
443295 transthyretin
111 3069 338305 apolipoprotein J/clusterin 1.5 6.40E-04
112 3079 1.64 4.47E-04
113 3133 178853 apolipoprotein E 1.49 8.66E-04
338057 apolipoprotein J/clusterin
114 3151 178853 apolipoprotein E 1.28 9.25E-03
338057 apolipoprotein J/clusterin
115 3249 4557325 apolipoprotein E 1.37 2.46E-03
178855 apolipoprotein J/clusterin
443295 transthyretin
116 3118 4557325/178853 apolipoprotein E 1.64 9.96E-04
117 5698 178855 apolipoprotein J/clusterin 1.73 5.82E-04
118 2819 40737343 C4B3 2 0.038 47
119 3137 4557325 apolipoprotein E 22.5 8.52E-07
Column 1, coded protein spot ID (as in Figure 1).
Column 2, biological variation analysis (BVA) number for spot generated by Decyder software.
Column 3, GI accession number(s) assigned to proteins identified by MASCOT.
Column 4, name of protein identified by MASCOT.
Column 5, fold-change in protein abundance; negative values indicate decreases in CDR 1 vs. CDR 0.
Column 6, p value of the CDR 1 versus CDR 0 comparison (Student’s t test).
Column 7, consecutive numbering identifying proteins as unique.
doi:10.1371/journal.pone.0016032.t002
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previous reports provide supporting evidence that this list of proteins
may contain viable candidate biomarkers for AD that are worthy of
pursuit in validation experiments.
Unsupervised Clustering Analysis
The intensity data from the 119 gel features of interest were
subjected to an unsupervised clustering analysis to evaluate their
ability to segregate the CDR 0 and CDR 1 samples, and to assess
their collective potential as a diagnostic biomarker panel (Figure 2).
The ‘heatmap’ generated from this analysis appeared to segregate
CDR 0 and CDR 1 individuals (indicated by green and red ovals,
respectively) almost completely, with only four participants
‘misclassified.’ However, closer examination revealed an addition-
al layer of segregation on the basis of APOE genotype (indicated by
‘ApoE 4+ Cluster’ and ‘ApoE 4 – Cluster’) which showed perfect
Figure 2. Unsupervised clustering of CSF samples by 2D-DIGE data from the 119 statistically significant gel features. (Student’s t-test,
a=0.05, present in .50% of images). Five gels containing hemoglobin (n=10 samples) were excluded. Columns represent samples; rows, numbered
1 through 119 from top to bottom, represent gel features depicted in Figure 1. Gel feature intensity is encoded colorimetrically from red (low
intensity) to green (high intensity); white indicates absent data. CDR status of individuals at time of CSF collection is encoded below by small green
(CDR 0) and red (CDR 1) ovals; CDR 0 and CDR 1 clusters are indicated below by green and red bars, respectively. APOE-e4 allele status of individuals
and groups, alike, is indicated by black (possessing ApoE4 protein, or one or two APOE-e4 alleles) or blue (possessing no ApoE4 protein, or no APOE-e4
alleles) bars. Rows representing gel features containing ApoE protein are indicated along the lower right border.
doi:10.1371/journal.pone.0016032.g002
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e16032Figure 3. Unsupervised clustering of CSF samples by 2D-DIGE data, excluding gel features containing apoE protein. All other
statistically significant gel features (Student’s t-test a=0.05, present in .50% of images) are retained. As in Figure 2, five gels containing hemoglobin
(n=10 samples) were excluded. Columns represent samples, numbered according to their original positions in Figure 2. Rows represent gel features,
numbered as in Figure 2; unlabeled rows are in consecutive order from upper number to lower number, with interruptions in sequence indicated by
labels. ApoE-containing features are removed. Gel feature intensity is encoded colorimetrically from red (low intensity) to green (high intensity); white
indicates absent data. CDR status of participants at time of CSF collection is encoded below, by small green (CDR 0) and red (CDR 1) ovals. APOE-e4
status (as described for Figure 2) is indicated by blue (ApoE4 negative) or black (ApoE4 positive) bars, below. Clustering pattern of samples
(numbered consecutively in order of appearance in Figure 2, from left to right) relative to Figure 2 is indicated by white numerals, below.
doi:10.1371/journal.pone.0016032.g003
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genetic risk factor for AD, some clustering of individuals by APOE
genotype might be expected simply from successful segregation of
CDR 0 and CDR 1 individuals. However, we hypothesize that the
apoE protein exerts a dominant clustering influence through the
markedly different electrophoretic profiles of its different isoforms
derived from APOE-e2, APOE-e3 and APOE- e4 alleles (illustrated
in Figure S1). ApoE was present in 24 of the 119 gel features found
to differ in intensity between the CDR groups, and was found to
be the primary protein in 12 of these gel features. This
heterogeneous electrophoretic mobility of apoE results from the
inherent charge differences of the three major apoE isoforms (-E2,
-E3, -E4) and the appearance of each isoform as an array of
multiple distinct gel features caused by post-translational modifi-
cations. These isoform-specific differences are reflected in the
prominent red and green clusters, located within the lower third of
Figure 2 (corresponding to gel features 83–90, 107–117, and 119),
that correlate very closely with participant APOE genotypes.
Recognizing this correlation, we hypothesized that APOE
genotypes were in large part driving the clustering of participant
samples in Figure 2. To test this hypothesis, we performed a
second unsupervised clustering analysis, including only those gel
features from the initial analysis that did not contain apoE protein
(Figure 3). Although this ‘apoE-free’ analysis segregated CDR 1
and CDR 0 groups less completely, it appropriately re-clustered
(by CDR status) several samples (#12, 36, 37) that were aberrantly
segregated in Figure 2, potentially due to their APOE genotypes.
Moreover, clustering of participant samples into APOE genotype
subgroups in Figure 3 appears negligible. The underlying benefit
of this ‘apoE-free’ analysis is that it reveals the sample-clustering
potential of other gel features, which was previously obscured by
the inclusion of apoE-containing gel features. As can now be better
visualized in Figure 3, gel features appearing within the upper
three-fourths of the heatmap appear to show greater intensity in
CDR 1 samples; the converse is true of gel features within the
lower fourth. It is important to note that measurements of Ab42
and tau (two proteins measured by ELISA and not detected by
2D-DIGE) were not included in these clustering analyses; because
these ‘discovery’ samples were selected for this study on the basis of
CSF Ab42 and tau levels, such inclusion would presumably yield
perfect or near-perfect segregation by CDR status in this
‘discovery’ cohort. Therefore, this analysis reflects the potential
of these candidate biomarkers to segregate CDR 0 and CDR 1
individuals independent of any contribution from current leading
CSF biomarkers Ab42 and tau. It does not address whether these
biomarker candidates might improve upon the utility of Ab42 and
tau, however.
Validation of Candidate Biomarkers by ELISA
Before evaluating a subset of these candidate biomarkers in a
larger independent sample set, we first assessed the capacity of
protein-specific quantitative ELISAs to detect significant differ-
ences between the CDR 0 and CDR 1 groups of the original
‘discovery’ cohort. When possible, to facilitate future reproduction
of our findings by other groups and potential translation to clinical
use, we applied commercially available ELISA kits.
Of the eleven ELISAs applied to the ‘discovery’ cohort (n=47,
one sample was unavailable for validation), six (NrCAM, YKL-40,
chromogranin A, carnosinase I, transthyretin, cystatin C) showed
statistically significant or near-significant differences between
CDR 0 and CDR 1 groups (Figure 4); five others (PEDF, beta-2
microglobulin, clusterin/apoJ, ceruloplasmin, apoE) did not.
The six ELISAs that measured differences between the CDR 0
and CDR 1 CSF samples of the ‘discovery’ cohort were
subsequently applied to a larger, independent set of CSF samples
(n=292) collected from volunteer participants studied by the WU-
ADRC. This ‘validation’ cohort included a CDR 0.5 group in
addition to CDR 0 and CDR 1 groups, allowing for biomarker
assessment in the very early clinical stage of AD. Demographic,
clinical, and genetic characteristics of these individuals at time of
sample collection are presented in Table 1. Unlike the ‘discovery’
cohort, this ‘validation’ cohort was not preselected on the basis of
prior biomarker values (CSF Ab42 and tau), although assays for
CSF Ab42, tau and p-tau181 were performed.
Because the age and gender compositions differed among the
clinical groups of the ‘validation cohort,’ we evaluated each of
these 9 biomarkers (six novel candidates, Ab42, tau, and p-tau181)
for age and gender correlations in order to apply covariate
analyses appropriately. Correlating with age were tau (r=0.318,
p,0.0001), p-tau181 (r=0.2216, p,0.001), Ab42 (r=20.2334,
p,0.0001) and YKL-40 (r=0.4001, p,0.001); no biomarkers
correlated with gender (p.0.05).
As shown in Figure 5, statistically significant differences between
clinically defined groups were measured for Ab42, tau, p-tau181,
NrCAM, YKL-40, chromogranin A, and carnosinase I; for
transthyretin and cystatin C, non-significant trends were mea-
sured. These differences appeared in three patterns: Ab42 showed
a pronounced decrease from CDR 0 to CDR 0.5 and a lesser
reduction from CDR 0.5 to CDR 1; tau, p-tau181, and YKL-40
showed increases that were equivalent in CDR 0.5 and CDR 1
relative to CDR 0; NrCAM, chromogranin A, and carnosinase I
showed decreases relative to CDR 0 only in CDR 1, and not in
CDR 0.5.
Diagnostic Utility of Validated Candidate Biomarkers
To evaluate and compare the potential of the validated
candidate biomarkers and Ab42, tau, and p-tau181 for identifying
either very mild to mild dementia (combined CDR 0.5 and CDR
1) or mild dementia (CDR 1), ROC curves and AUCs were
calculated for each biomarker using data from the ‘validation’
cohort (Figure 6A, B, Tables 3, 4). Stepwise logistic regression
analyses indicated that, among the nine biomarkers under
consideration, YKL-40, NrCAM and tau yielded the highest
AUC (0.896) in discriminating cognitive normalcy (CDR 0) from
very mild to mild dementia (CDR.0) (Figure 6C, Table 3); for
discriminating mild dementia (CDR 1) from CDR,1, carnosinase
I, chromogranin A and tau yielded the highest AUC (0.876)
(Figure 6D, Table 4).
Discussion
Using an unbiased proteomics approach (2D-DIGE LC-MS/
MS), this study identified 47 novel candidate CSF protein
biomarkers for early AD. Subsequently, by evaluating a subset
of these candidate biomarkers by ELISA, this study validated the
Figure 4. Quantitative ELISAs for 11 biomarker candidates applied to ‘discovery’ cohort CSF samples (n=47). Each assay performed in
triplicate; mean value reported for each sample. The six assays represented in the upper two rows (A. YKL-40, B. Transthyretin, C. NrCAM, D.
Chromogranin A, E. Carnosinase I, and F. Cystatin C) measured differences between CDR 0 and CDR 1 groups (unpaired t-test); the five assays
represented in the lower two rows (G. ApoE, H. PEDF, I. Clusterin, J. Ceruloplasmin, K. b-2 microglobulin) did not.
doi:10.1371/journal.pone.0016032.g004
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PLoS ONE | www.plosone.org 12 January 2011 | Volume 6 | Issue 1 | e16032Figure 5. Six biomarker candidates and established biomarkers tau, p-tau181 and Ab42 in ‘validation’ cohort CSF (n=292). Each
candidate biomarker assay was performed in triplicate, with one mean value reported for each sample; assays for tau, p-tau181 and Ab42 were
performed in duplicate. In addition to A. tau, B. p-tau181 and C.A b42 (top row), four assays (D. YKL-40, E. carnosinase I, F. chromogranin A, G.
NrCAM) measured statistical differences between clinically defined groups, as indicated; H. transthyretin and I. cystatin C did not reach criterion
(a=0.05) for any comparisons. *p ,0.05; * * p,0.01; * * * p, 0.001; * ***p ,0.0001; solid circle p,0.05 by LSD only; double solid circle
p,0.05 by unpaired t-test and Mann-Whitney, not by unpaired t-test with Welch’s correction.
doi:10.1371/journal.pone.0016032.g005
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mild, very mild, or no dementia (CDR 1, 0.5, 0, respectively).
Further statistical analyses demonstrated that these biomarkers
could improve the accuracy of ‘established’ biomarkers Ab42 and
tau for the diagnosis of early AD.
The results from the 2D-DIGE LC-MS/MS portion of this study
suggest that many of the recognized neuropathological changes of
AD are represented by changes in the CSF proteome. Most of the
47 candidate biomarker proteins identified in this study can be
placed into structural and/or functional categories (e.g. synaptic
adhesion, synaptic function, dense core synaptic vesicle proteins,
inflammation/complement, protease activity/inhibition, apolipo-
proteins, etc.) associated with accepted neuropathophysiological
changes in AD (Table 5). Unsupervised clustering analyses of these
2D-DIGE data, performed without the influence of CSF Ab42, tau,
p-tau181 and APOE genotype, additionally suggest that these
biomarker candidates collectively show utility for discriminating
groups with and without mild DAT (Figure 3).
In the second phase of this study, designed to measure a subset
of candidate biomarker proteins in two independent sample sets by
ELISA, four of the eleven candidate biomarkers that were tested
showed capacity to distinguish clinical groups. However, seven
candidate biomarkers did not show statistically significant
differences between clinical groups in either the smaller ‘discovery’
cohort or the larger ‘validation’ cohort. Superficially, this ‘failure
rate’ might cast doubt on the list of candidate biomarkers
identified through 2D-DIGE. However, it is important to note
that 2D-DIGE is sensitive to changes in concentrations of minor
protein isoforms and post-translational modifications that may not
significantly alter the global concentrations of a ‘parent’ protein,
which would be measured by ELISA. Therefore, it is not
surprising that some of the candidate biomarker ELISAs did not
replicate the findings from 2D-DIGE. Transthyretin provides a
prime example: all of the significant gel-features ascribed to
transthyretin (gel features # 20, 52, 57, 58, 60, 77, 78, 79, 84, 87,
110, 115; Table 2) showed unusual electrophoretic patterns and
Figure 6. Receiver Operating Characteristic (ROC) curves of ELISA data from ‘validation’ cohort. Simple ROC analyses were performed
for each biomarker to distinguish A. CDR.0 from CDR 0 (‘‘earlier diagnosis’’) and B. CDR 1 from CDR,1 (‘‘early diagnosis’’). Stepwise logistic
regression models were used to identify combinations of these biomarkers that would distinguish C. CDR.0 from CDR 0 (‘‘earlier diagnosis’’),
AUC=0.90 and D. CDR 1 from CDR,1 (‘‘early diagnosis’’), AUC=0.88.
doi:10.1371/journal.pone.0016032.g006
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not individually show statistical differences (Figure 1). In fact,
whereas most of the significant transthyretin 2D-DIGE gel features
were decreased in AD, the global transthyretin levels measured by
ELISA in the ‘discovery’ and ‘validation’ cohorts were actually
mildly increased in groups with cognitive impairment (CDR.0)
relative to those without (CDR 0) (Figures 4 and 5). To measure
the sub-species of transthyretin that were identified by 2D-DIGE
as decreasing in AD will require assays that specifically target
relevant post-translational modifications and exclude other forms
of transthyretin. Similarly, other 2D-DIGE biomarker candidates
may also require specifically tailored assays for accurate, high-
throughput measurement.
Nevertheless, four candidate biomarkers were successfully
validated in both cohorts, and two others showed non-significant
trends by ELISA in the larger ‘validation’ cohort (Figure 5). This
larger cohort represented three different cognitive stages: normal-
cy, very mild dementia, and mild dementia (CDR 0, CDR 0.5,
CDR 1, respectively), and revealed different patterns of CSF
biomarker levels, vis-a-vis cognitive status. The CSF concentration
of YKL-40, an astrocytic marker of plaque-associated neuroin-
flammation [137–148], is increased by the very earliest stage of
clinical disease (CDR 0.5). Transthyretin [24,87,173,175,179–
184] and cystatin C [22,173,185–188], two proteins with
neuroprotective qualities that are implicated in preventing
amyloidogenesis of Ab peptide, show a similar pattern. In contrast,
the concentrations of NrCAM, a synaptic adhesion molecule
[19,46–49], chromogranin A, a dense core synaptic vesicle protein
[19,20,22,59–62], and carnosinase I, a neuronal dipeptidase
responsible for degradation of the anti-oxidant and metal-
chelating dipeptide carnosine [33,107–111] do not decline until
mild dementia ensues (CDR 1).
Like the current leading CSF biomarkers for AD (Ab42, tau and
p-tau181), all of these biomarker candidates show ranges with
substantial overlap between clinically defined groups. This issue of
overlapping values, common among candidate AD CSF biomark-
ers reported to date, suggests that any one biomarker will be
insufficient to accurately identify early AD, and that an ensemble
of complementary biomarkers will be required to provide
adequate sensitivity and specificity. Therefore, to identify an
optimal combination of these biomarkers that can distinguish the
early clinical stages of AD from cognitive normalcy, we applied
Table 3. Receiver Operating Characteristic Curve Areas for CDR 0 vs ,0 Comparison.
Biomarker Area Under Curve Standard Error 95% Confidence Interval
Tau 0.8004 0.0279 0.7457–0.8551
Ab42 0.7429 0.0315 0.6812–0.8046
p-tau181 0.7339 0.0315 0.6721–0.7956
YKL-40 0.6717 0.0349 0.6033–0.7401
Transthyretin 0.6190 0.0331 0.5541–0.6838
Carnosinase I 0.5735 0.0365 0.5020–0.6450
NrCAM 0.5422 0.0355 0.4726–0.6118
Chromogranin A 0.5303 0.0373 0.4572–0.6034
Cystatin C 0.5297 0.0366 0.4579–0.6014
Logistic Regression 0.8955 0.0212 0.8539–0.9372
ROC analyses of ‘validation’ cohort ELISA data were performed for each biomarker to distinguish CDR.0 from CDR 0 (‘‘earlier diagnosis’’). A stepwise logistic regression
model, applied to identify a complementary combination of these biomarkers that would optimize accuracy (maximize area under the curve [AUC]) without including
additional non-contributory biomarkers, accepted tau, YKL-40 and NrCAM and yielded an AUC of 0.8955 (‘‘Logistic Regression,’’ lowest row).
doi:10.1371/journal.pone.0016032.t003
Table 4. Receiver Operating Characteristic Curve Areas for CDR 1 vs ,1 Comparison.
Biomarker Area Under Curve Standard Error 95% Confidence Interval
Ab42 0.7690 0.0376 0.6953–0.8427
Tau 0.7502 0.0420 0.6679–0.8325
Carnosinase I 0.7277 0.0512 0.6273–0.8281
Chromogranin A 0.6879 0.0566 0.5771–0.7988
Transthyretin 0.6605 0.0380 0.5860–0.7350
p-tau181 0.6512 0.0483 0.5566–0.7458
NrCAM 0.6411 0.0553 0.5326–0.7495
YKL-40 0.6271 0.0532 0.5228–0.7313
Cystatin C 0.5752 0.0565 0.4645–0.6858
Logistic Regression 0.8762 0.0314 0.8147–0.9377
ROC analyses of ‘validation’ cohort ELISA data were performed for each biomarker to distinguish CDR 1 from CDR,1 (‘‘early diagnosis’’). A stepwise logistic regression
model, applied to identify a complementary combination of these biomarkers that would optimize accuracy (maximize area under the curve [AUC]) without including
additional non-contributory biomarkers, accepted tau, carnosinase I and chromogranin A, yielding an AUC of 0.8762 (‘‘Logistic Regression,’’ lowest row).
doi:10.1371/journal.pone.0016032.t004
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Functional/Structural Category Protein References
Adhesion molecules N-Cadherin [39-45]
NrCAM [19,46-49]
Calsyntenin [47,50-53]
Neuronal Pentraxin Receptor [47,54]
Brain Associated Small Cell Lung Cancer Antigen (NCAM-140/CD56) [55]
Nectin-like molecule-1/TSLL1/SynCam3 [56-58]
Dense core vesicles Chromogranin A [19,20,22,59-62]
Chromogranin B [60,62]
Secretogranin II [60-63]
Secretogranin III [59,64,65]
VGF NGF Inducible precursor [20,22,23,66-69]
Carboxypeptidase E [70-75]
Synaptic/Neuronal metabolism Aspartate aminotransferase I [76-82]
Synaptic Function S100A1 [83]
Neuronal Pentraxin Receptor [27,47,54]
Brain Acetylcholinesterase Putative Membrane Anchor (CutA1) [84,85]
Calsyntenin [47,50-53]
Neuroprotection PEDF (Serpin-F1) [86-96]
Annexin I [97-99]
Prosaposin [20,100-103]
Secretogranin II [104-106]
Carnosinase I [33,107-111]
Extracellular superoxide dismutase (SOD3) [112-114]
Apoptosis/Actin remodeling Gelsolin [115-121]
Prk-1 (PKN) [122-126]
Synaptic plasticity/Learning and memory VGF NGF inducible precursor [20,22,23,66-69]
NrCAM [19,46-49]
b3GnT1 [49,127,128]
Carnosinase I [33,107-111]
Carbonic Anhydrase IV [129-131]
S100A1 [132]
Carboxypeptidase E [70-75]
Calmodulin [133-136]
Extracellular superoxide dismutase (SOD3) [114]
Inflammation/Complement *YKL-40/Chitinase 3-Like 1 [137-148]
PEDF (Serpin-F1) [86-96]
Annexin I [97-99]
IHRP/ITIH4 [149,150]
Vitronectin [151-155]
*Complement C4B3 [156-161]
Kininogen I [162,163]
Chromogranin A [19,20,22,59-62]
Secretogranin III [59,64,65]
Apolipoprotein J [27,152,156,157,164-167]
Beta 2-microglobulin [168-171]
Extracellular superoxide dismutase (SOD3) [172]
Prostaglandin metabolism *Prostaglandin H2 D Isomerase/Beta-trace [162,173-175]
Amyloid beta peptide binding/Amyloidogenesis *Apolipoprotein A1 (proapolipoprotein) [176,177]
Apolipoprotein E [178]
Apolipoprotein J [27,152,156,157,164-167]
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‘validation’ cohort (Figure 6, Tables 3 and 4). These analyses
suggest that four candidate AD biomarkers (YKL-40, NrCAM,
chromogranin A, carnosinase I) can improve the ability of tau to
classify individuals into CDR 0, CDR 0.5 and CDR 1 groups with
appreciable accuracy.
It may appear counter-intuitive that Ab42 and p-tau181, which
individually discriminate very mild AD and mild AD from
cognitively normal groups quite well, were not incorporated into
either ‘optimal’ biomarker panel by the stepwise logistic regression
analyses. Likewise, NrCAM was included in the optimal CDR 0 vs
CDR.0 biomarker panel (AUC 0.896) even though its mean
levels did not independently show a statistical difference between
CDR 0 and CDR.0 groups. In considering this outcome, it may
be worth noting that if NrCAM, transthyretin, chromogranin and
cystatin C are removed from consideration, the stepwise logistic
Functional/Structural Category Protein References
Transthyretin [87,173,175,179-184]
Gelsolin [115-121]
Vitronectin [151-155]
Cystatin C [22,173,185-188]
*Prostaglandin H2 D Isomerase/Beta-trace [162,173-175]
*a-2-macroglobulin [19,189-194]
*a-1-antichymotrypsin [33,195-199]
Protease activity *a-1-antichymotrypsin [33,195-199]
*a-2-macroglobulin [19,189-194]
Cystatin C [22,173,185-188]
Carboxypeptidase E [70-75]
Matrix proteins Fibulin 3 (EFEMP1) [200-202]
Vitronectin [151-155]
Phospholipase activity Annexin I (Lipocortin) [97-99]
Prosaposin [20,100-103]
Apolipoproteins *Apolipoprotein A1 (proapolipoprotein) [24,165,166,176,177,203,204]
Apolipoprotein CII [25,166,205]
Apolipoprotein CIII [25,206,207]
Apolipoprotein E [24,27,165,204]
Apolipoprotein J [27,152,156,157,164-167]
*Apolipoprotein H [19,25,165,208,209]
Calcium binding/homeostasis Calmodulin [134-136]
S100A1 [83,210]
Annexin I (Lipocortin) [97-99]
Calsyntenin [47,50-53]
Gelsolin [115-121]
Metal (Copper and Iron) Binding Carnosinase I [33,107-111]
Ceruloplasmin [211-217]
Brain Acetylcholinesterase Putative Membrane Anchor (CutA1) [84,85]
Chaperone complex/activity S100A1 [218]
Transthyretin (prealbumin) [24,87,173,175,179-184]
Endoplasmic Reticulum - Associated Degradation Man9-mannosidase [219-221]
Extracellular and Intraneuronal pH Carbonic Anhydrase IV [129-131]
Carnosinase I [33,107-111]
Glycobiology (lactosamine synthesis) b3GnT1 [49,127,128]
Hemodynamics Angiotensinogen [172,222]
Extracellular superoxide dismutase (SOD3) [172]
Thyroid hormone transport Transthyretin (prealbumin) [24,87,173,175,179-184]
Unknown Hypothetical protein
CSF biomarkers are grouped according to reported function(s) and, when appropriate, cellular locations. Asterisks (*) indicate those biomarkers found to be increased in
AD CSF; the vast majority were decreased.
doi:10.1371/journal.pone.0016032.t005
Table 5. Cont.
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‘optimal’ biomarker panel that includes only tau, Ab42 and
carnosinase I, with an AUC of 0.849 (not shown). In this restricted
analysis, the paired contribution of Ab42 and carnosinase I to tau
is apparently greater than that of YKL-40. These analyses
illustrate how ‘unpredictable’ and context-dependent optimal
biomarker combinations can be, and suggest that biomarker
complementarity may be more important to consider than each
biomarker’s independent performance, when choosing a biomark-
er panel. Of course, it will be necessary to replicate these findings
in additional independent cohorts. It will also be essential to
evaluate a greater number of candidate biomarkers in similar
fashion, in order to construct a biomarker panel with even greater
accuracy.
Another worthwhile feature to consider when evaluating and
selecting CSF biomarkers is relative concentration in the blood
(plasma, serum), because biomarker measurements in CSF can be
artifactually influenced by subtle blood contamination at the time
of lumbar puncture; from this perspective, ideal CSF biomarkers
show CSF concentrations that are equal to or greater than those in
blood. An additional reason to assess plasma/serum concentra-
tions of candidate CSF biomarkers is to determine if venipuncture,
which is more easily performed than lumbar puncture, might yield
equivalent information. Among the six CSF biomarkers identified
by stepwise logistic regression analysis in the current study, Ab42
and tau [8–11], YKL-40 [137], and chromogranin A [223] show
higher levels in CSF than in plasma; carnosinase I levels appear
similar in CSF and serum [110]; NrCAM levels appear higher in
serum than in CSF, although the forms of NrCAM present in
these fluids may differ [224]. Concerning independent utility as
biomarkers for AD, only plasma YKL-40 and serum NrCAM
have shown promise [137,225], albeit inferior to that of CSF
YKL-40 and NrCAM demonstrated here. Plasma tau concentra-
tions in AD and controls are below the level of detection of the
most commonly used tau assays, and plasma Ab42 [8–11] and
plasma chromogranin A (R.Perrin et al., unpublished data)
concentrations show no significant differences among CDR
groups. Serum carnosinase activity likewise has not shown
significant differences between AD and controls in one small
study [111], though a difference between AD and mixed dementia
(including vascular dementia) has been reported [111]. To our
knowledge, an evaluation of plasma or serum carnosinase I
concentrations in the context of AD has not yet been performed or
reported. Further assessment of the potential of these and other
proteins as candidate AD biomarkers in plasma or serum,
complete with evaluation of their performance as ensembles,
remains an important task for future studies. Currently, however,
this panel of six biomarkers appears likely to show much greater
promise in its application to CSF.
Indeed, by providing proof of concept, this study outlines a
scheme to categorize the early stages of AD using CSF protein
biomarkers that reflect established features of the pathophysiolog-
ical evolution of the disease (Figure 7). Building upon previous
findings that low CSF Ab42 can identify cognitively normal
individuals with plaques (preclinical AD) [8,11], and that tau/
Ab42 and YKL-40/Ab42 ratios can predict risk of developing
Figure 7. Hypothetical model defines early stages of AD by temporal pattern of CSF protein biomarker levels. The horizontal bar
(below) describes the early clinicopathological progression from cognitive normalcy without AD pathology (‘Non-AD’) to mild dementia in six
stages. As depicted by the curves above, Non-AD CSF has high Ab42 (red line), high chromogranin A (Chr A), carnosinase I (Carno I) and NrCAM
(green line), and low YKL-40 and tau (blue line). Reduced CSF Ab42 correlates with amyloid plaque deposits, the first sign of neuropathologically
identifiable AD (‘preclinical AD’) [8]. CSF Ab42 appears to decrease further as cognition declines from normal (Clinical Dementia Rating [CDR] 0)t o
very mild cognitive impairment (MCI, CDR 0.5) to mild dementia (CDR 1). When considered as ratios with Ab42, CSF markers of neuroinflammation
(e.g. YKL-40) and neurofibrillary tangle pathology (e.g. tau) appear to increase before and predict the onset of very mild cognitive impairment (MCI,
CDR 0.5), defining a CDR 0 group ‘At Risk’ for cognitive decline [9,15,137]; YKL-40 and tau also appear to be higher among those who progress
rapidly from very mild to mild dementia, defining a CDR 0.5 group ‘At Risk’ for impending cognitive decline [137,230]. Reductions in synapse-
associated (NrCAM, chromogranin A) and neuronal (carnosinase I) proteins, and increases in YKL-40 and tau mirror the progression and anatomical
spread of synaptic and neuronal losses, gliosis and tau pathology associated with cognitive decline, and can be used to define CDR 0.5 and CDR 1.
doi:10.1371/journal.pone.0016032.g007
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biomarkers (YKL-40, NrCAM, chromogranin A, carnosinase I,
tau and Ab42) begins to segregate individuals into six clinico-
pathological categories: normal cognition without amyloid
plaques, normal cognition with amyloid plaques (preclinical AD),
normal cognition at increased risk to develop dementia (convert-
ers), very mild dementia (CDR 0.5), very mild dementia at
increased risk for progression, and mild dementia (CDR 1)
(Figure 7).
We acknowledge that this minimal panel of biomarkers
currently has insufficient sensitivity and specificity for clinical
application, particularly because it has not been fully evaluated for
its ability to discriminate AD from non-AD causes of dementia
(although Ab42, p-tau181, tau, and specific fragments of
chromogranin A and cystatin C have shown some ability to
distinguish AD from frontotemporal lobar degeneration [FTLD])
[22,226,227]. The incorporation of additional biomarkers that are
likely to discriminate early AD from cognitive normalcy, such as
those identified in the first phase of this study, or other biomarkers
that have already shown promise for distinguishing AD from other
leading causes of dementia (e.g. agouti related peptide, eotaxin-3,
and hepatocyte growth factor [19], complement C3a des-arg and
integral membrane protein 2B CT [22], for FTLDs; and alpha-
synuclein [228], apoH and vitamin D binding protein [25] for
Lewy body disorders), would likely improve the panel’s diagnostic
utility. However, even in its current form, this initial panel might
show value if applied in the context of clinical trial design, wherein
simple enrichment of study populations for characteristics of
interest would increase efficiency and power and reduce duration
and cost. A biomarker panel like this one might also allow clinical
trials to evaluate stage-specific responses to treatment, which may
differ. Finally, because most of these biomarkers reflect underlying
pathological changes in real time, it is appealing to speculate that
these biomarkers may have additional utility for evaluating
clinically imperceptible treatment responses (as in [229]) and for
monitoring neuropathological – rather than cognitive – decline.
Supporting Information
Figure S1 ApoE protein isoforms appear in different gel
features on 2D-DIGE. Overlays of fluorescent 2D-DIGE
images from gels representing CSF from two individuals with
homozygosity for APOE-e2 (green) or APOE-e3 (red) (panel A) and
for APOE-e3 (green) or APOE-e4 (red) (panel B) illustrate the
heterogeneity of signal distribution by isoelectric point and
molecular weight among apoE protein isoforms derived from
different alleles. In panels C, D, E, F, G, H, signal intensities of
individual CSF samples, grouped by genotype (2/2, 3/3 and 4/4
represent homozygotes; 2/3, 3/4 represent heterozygotes) are
indicated for six apoE gel features (labeled C, D, E, F, G, H in
panels A and B), illustrating that gel features C and D represent
apoE2; gel feature E represents multiple forms; gel feature F
represents apoE3; and gel features G and H, apoE4.
(TIF)
Table S1 Mass spectrometry and protein identification
data for 2D-DIGE gel features that differ in AD CSF.
Results are ordered sequentially by ‘‘heat map #’’ [column A],
corresponding to the ‘heat map’ row numbers in Figure 2. ‘‘Spot’’
[column B] refers to BVA number (see Methods). ‘‘(Accession)
primary protein name’’ [column C] provides the gi number and
protein name from the NCBI database. ‘‘Protein molecular
weight’’ [column D] is the gene product molecular weight in
Daltons. ‘‘Protein score’’ [column E] is the MASCOT-generated
protein score. ‘‘Protein ID probability’’ [column F] indicates
Scaffold’s percent probability that the protein identification is
correct. ‘‘Spectral count’’ [column G] is the number of spectra
assigned to the protein by Scaffold. ‘‘Unique proteins’’ [column H]
refers to the number of recognized tryptic peptides attributed to
the protein by MASCOT. ‘‘Peptide sequence’’ [column I]
indicates the amino acid sequence of the tryptic peptide predicted
by MASCOT. ‘‘MASCOT ion score’’ [column J] is the
MASCOT quality assessment of the peptide sequence assignment.
‘‘M/Z (observed)’’ [column K] is mass/charge ratio. ‘‘Mass
(observed)’’ [column L] of peptide is indicated in Daltons. ‘‘Mass
(theoretical)’’ [column M] is idealized tryptic peptide mass as
predicted by NCBI. ‘‘Mass error (ppm)’’ [column N] is the error in
parts per million determined through comparison of theoretical
peptide mass to data generated by mass spectrometry. ‘‘MS
source’’ [column O] reflects the mass spectrometer that produced
the observed data (Q-STAR or LTQ-FT). ‘‘Modifications’’
[column P] lists variable post-translational modifications identified
by mass spectrometry peptide sequence analysis.
(XLS)
Acknowledgments
The authors would like to express our appreciation to the Biomarker Core,
Clinical Core, Data Management and Statistics Core, Genetics Core,
lumbar puncture physicians, and volunteer participants of the Knight
ADRC of Washington University in St. Louis, and to the volunteer
participants of the University of Washington, the Oregon Health and
Science University, the University of Pennsylvania, and the University of
California San Diego.
Author Contributions
Conceived and designed the experiments: RJP RC-S DMH JCM AMF
RRT. Performed the experiments: RJP RC-S JPM AED PG RRT ARS.
Analyzed the data: RJP RC-S JPM AED PG RRT ARS CMR DMH
AMF. Contributed reagents/materials/analysis tools: RRT ERP GL DRG
CMC JFQ JAK DMH JCM AMF. Wrote the paper: RJP RC-S JPM
RRT. All authors revised the manuscript for important intellectual content
and gave final approval of the version to be published.
References
1. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in
different age categories. Neurobiol Aging 18: 351–357.
2. Morris J, Price J (2001) Pathologic correlates of nondemented aging, mild
cognitive impairment, and early stage Alzheimer’s disease. J Mol Neurosci 17:
101–118.
3. Price J, Ko A, Wade M, Tsou S, McKeel D, et al. (2001) Neuron number in the
entorhinal cortex and CA1 in preclinical Alzheimer’s disease. Arch Neurol 58:
1395–1402.
4. Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA (2006) Memory
complaints are related to Alzheimer disease pathology in older persons.
Neurology 67: 1581–1585.
5. Markesbery W, Schmitt F, Kryscio R, Davis D, Smith C, et al. (2006)
NeuropathologicsubstrateofMild Cognitive Impairment.ArchNeurol 63: 38–46.
6. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood J, et al.
(1995) Reduction of b-amyloid peptide42 in the cerebrospinal fluid of patients
with Alzheimer’s disease. Ann Neurol 38: 643–648.
7. Sunderland T, Linker G, Mirza N, Putnam K, Friedman D, et al. (2003)
Decreased b-amyloid1-42 and increased tau levels in cerebrospinal fluid of
patients with Alzheimer’s disease. JAMA 289: 2094–2103.
8. Fagan A, Mintun M, Mach R, Lee S-Y, Dence C, et al. (2006) Inverse relation
between in vivo amyloid imaging load and CSF Ab42 in humans. Ann Neurol
59: 512–519.
Novel CSF Biomarkers for Early Alzheimer’s Disease
PLoS ONE | www.plosone.org 19 January 2011 | Volume 6 | Issue 1 | e160329. Fagan A, Roe C, Xiong C, Mintun M, Morris J, et al. (2007) Cerebrospinal
fluid tau/Ab42 ratio as a prediction of cognitive decline in nondemented older
adults. Arch Neurol 64: 343–349.
10. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, et al. (2009) Decreased
cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively
normal elderly. Ann Neurol 65: 176–183.
11. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, et al. (2009)
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition
in cognitively normal individuals: implications for future clinical trials of
Alzheimer’s disease. EMBO Mol Med 1: 371–380.
12. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, et al.
(2009) Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-
FDDNP binding. J Nucl Med 50: 1464–1470.
13. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, et al.
(2009) Beta amyloid in Alzheimer’s disease: increased deposition in brain is
reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65:
927–934.
14. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, et al. (2009)
Relationships between biomarkers in aging and dementia. Neurology 73:
1193–1199.
15. Li G, Sokal I, Quinn J, Leverenz J, Brodey M, et al. (2007) CSF tau/Ab42 ratio
for increased risk of mild cognitive impairment: A follow-up study. Neurology
69: 631–639.
16. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, et al. (2009) Cerebrospinal
fluid biomarkers and rate of cognitive decline in very mild dementia of the
Alzheimer type. Arch Neurol 66: 638–645.
17. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, et al. (2005)
Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer
disease. J Alzheimers Dis 7: 125–133; discussion 173–180.
18. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, et al. (2007)
Classification and prediction of clinical Alzheimer’s diagnosis based on plasma
signaling proteins. Nat Med 13: 1359–1362.
19. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, et al. (2010)
Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment.
Acta Neuropathol 119: 669–678.
20. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, et al. (2008)
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer’s
disease. Neurobiol Aging 29: 961–968.
21. Simonsen A, McGuire J, Hansson O, Zetterberg H, Podust V, et al. (2007)
Novel panel of cerebrospinal fluid biomarkers for the prediction of progression
to Alzheimer dementia in patients with mild cognitive impairment. Arch
Neurol 64: 366–370.
22. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, et al.
(2007) A novel panel of cerebrospinal fluid biomarkers for the differential
diagnosis of Alzheimer’s disease versus normal aging and frontotemporal
dementia. Dement Geriatr Cogn Disord 24: 434–440.
23. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, et al. (2003) A
panel of cerebrospinal fluid potential biomarkers for the diagnosis of
Alzheimer’s disease. Proteomics 3: 1486–1494.
24. Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L,
et al. (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer
patients. Neuroreport 13: 611–615.
25. Abdi F, Quinn J, Jankovic J, McIntosh M, Leverenz J, et al. (2006) Detection of
biomarkers with a multiplex quantitative proteomic platform in cerebrospinal
fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9:
293–348.
26. Choe L DAM, Relkin NR, Pappin D, Ross P, Williamson B, Guertin S, Pribil P,
Lee KH (2007) 8-plex quantitation of changes in cerebrospinal fluid protein
expression in subjects undergoing intravenous immunoglobulin treatment for
Alzheimer’s disease. Proteomics 7: 3651–3660.
27. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal
fluid proteomic biomarkers for Alzheimer’s disease. Ann Neurol 61: 120–129.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984)
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA
Work Group under the auspices of Department of Health and Human Services
Task Force on Alzheimer’s Disease. Neurology 34: 939–944.
29. Morris JC (1993) The Clinical Dementia Rating (CDR). Current version and
scoring rules. Neurology 43: 2412–2414.
30. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr., et al. (1994) An
increased percentage of long amyloid beta protein secreted by familial amyloid
beta protein precursor (beta APP717) mutants. Science 264: 1336–1340.
31. Storandt M, Grant E, Miller J, Morris J (2006) Longitudinal course and
neuropathologic outcomes in original vs revised MCI and in pre-MCI.
Neurology 67: 467–473.
32. Hu Y, Malone J, Fagan A, Townsend R, Holtzman D (2005) Comparative
proteomic analysis of intra- and interindividual variation in human
cerebrospinal fluid. Mol & Cell Proteom 4: 2000–2009.
33. Hu Y, Hosseini A, Kauwe J, Gross J, Cairns N, et al. (2007) Identification and
validation of novel CSF biomarkers for early stages of Alzheimer’s disease.
Proteomics - Clin Appl 1: 1373–1384.
34. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, et al. (2003) A novel
experimental design for comparative two-dimensional gel analysis: two-
dimensional difference gel electrophoresis incorporating a pooled internal
standard. Proteomics 3: 36–44.
35. Havlis J TH, Sebela M, Shevchenko A (2003) Fast-response proteomics by
accelerated in-gel digestion of proteins. Anal Chem 75: 1300–1306.
36. King J, Gross J, Lovly C, Rohrs H, Piwnica-Worms H, et al. (2006) Accurate
mass-driven analysis for the characterization of protein phosphorylation. Study
of the human chk2 protein kinase Anal Chem 78: 2171–2181.
37. Bredemeyer A, Lewis R, Malone J, Davis A, Gross J, et al. (2004) A proteomic
approach for the discovery of protease substrates. Proc Natl Acad Sci USA 101:
11785–11790.
38. Liu H, Sadygov RG, Yates JR, 3rd (2004) A model for random sampling and
estimation of relative protein abundance in shotgun proteomics. Anal Chem
76: 4193–4201.
39. Uemura K, Lill CM, Banks M, Asada M, Aoyagi N, et al. (2009) N-cadherin-
based adhesion enhances Abeta release and decreases Abeta42/40 ratio.
J Neurochem 108: 350–360.
40. Mysore SP, Tai CY, Schuman EM (2007) Effects of N-cadherin disruption on
spine morphological dynamics. Front Cell Neurosci 1: 1.
41. Bekirov IH NV, Svoronos A, Huntley GW, Benson DL (2008) Cadherin-8 and
N-cadherin differentially regulate pre- and postsynaptic development of the
hippocampal mossy fiber pathway. Hippocampus 18: 349–363.
42. Jang YN, Jung YS, Lee SH, Moon CH, Kim CH, et al. (2009) Calpain-
mediated N-cadherin proteolytic processing in brain injury. J Neurosci 29:
5974–5984.
43. Kubota K, Inoue K, Hashimoto R, Kumamoto N, Kosuga A, et al. (2009)
Tumor necrosis factor receptor-associated protein 1 regulates cell adhesion and
synaptic morphology via modulation of N-cadherin expression. J Neurochem
110: 496–508.
44. Latefi NS, Pedraza L, Schohl A, Li Z, Ruthazer ES (2009) N-cadherin
prodomain cleavage regulates synapse formation in vivo. Dev Neurobiol 69:
518–529.
45. Schrick C, Fischer A, Srivastava DP, Tronson NC, Penzes P, et al. (2007) N-
cadherin regulates cytoskeletally associated IQGAP1/ERK signaling and
memory formation. Neuron 55: 786–798.
46. Kalus I, Bormann U, Mzoughi M, Schachner M, Kleene R (2006) Proteolytic
cleavage of the neural cell adhesion molecule by ADAM17/TACE is involved
in neurite outgrowth. J Neurochem 98: 78–88.
47. Yin GN, Lee HW, Cho JY, Suk K (2009) Neuronal pentraxin receptor in
cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
Brain Res 1265: 158–170.
48. Aisa B, Gil-Bea FJ, Solas M, Garcı ´a-Alloza M, Chen CP, et al. (2010) Altered
NCAM Expression Associated with the Cholinergic System in Alzheimer’s
Disease. J Alzheimers Dis 20: 659–668.
49. Storan MJ, Magnaldo T, Biol-N’Garagba MC, Zick Y, Key B (2004)
Expression and putative role of lactoseries carbohydrates present on NCAM
in the rat primary olfactory pathway. J Comp Neurol 475: 289–302.
50. Konecna A, Frischknecht R, Kinter J, Ludwig A, Steuble M, et al. (2006)
Calsyntenin-1 docks vesicular cargo to kinesin-1. Mol Biol Cell 17: 3651–3663.
51. Ludwig A, Blume J, Diep TM, Yuan J, Mateos JM, et al. (2009) Calsyntenins
Mediate TGN Exit of APP in a Kinesin-1-Dependent Manner. Traffic 10:
572–589.
52. Vogt L, Schrimpf SP, Meskenaite V, Frischknecht R, Kinter J, et al. (2001)
Calsyntenin-1, a proteolytically processed postsynaptic membrane protein with
a cytoplasmic calcium-binding domain. Mol Cell Neurosci 17: 151–166.
53. Hintsch G, Zurlinden A, Meskenaite V, Steuble M, Fink-Widmer K, et al.
(2002) The calsyntenins—a family of postsynaptic membrane proteins with
distinct neuronal expression patterns. Mol Cell Neurosci 21: 393–409.
54. Cho RW, Park JM, Wolff SB, Xu D, Hopf C, et al. (2008) mGluR1/5-
dependent long-term depression requires the regulated ectodomain cleavage of
neuronal pentraxin NPR by TACE. Neuron 57: 858–871.
55. Umezawa Y, Kuge S, Kikyo N, Shirai T, Watanabe J, et al. (1991) Identity of
brain-associated small cell lung cancer antigen and the CD56 (NKH-1/Leu-19)
leukocyte differentiation antigen and the neural cell adhesion molecule.
Jpn J Clin Oncol 21: 251–255.
56. Kakunaga S, Ikeda W, Itoh S, Deguchi-Tawarada M, Ohtsuka T, et al. (2005)
Nectin-like molecule-1/TSLL1/SynCAM3: a neural tissue-specific immuno-
globulin-like cell-cell adhesion molecule localizing at non-junctional contact
sites of presynaptic nerve terminals, axons and glia cell processes. J Cell Sci 118:
1267–1277.
57. Gao J, Chen T, Hu G, Gong Y, Qiang B, et al. (2008) Nectin-like molecule 1 is
a glycoprotein with a single N-glycosylation site at N290KS which influences its
adhesion activity. Biochim Biophys Acta 1778: 1429–1435.
58. Fogel AI, Akins MR, Krupp AJ, Stagi M, Stein V, et al. (2007) SynCAMs
organize synapses through heterophilic adhesion. J Neurosci 27: 12516–12530.
59. Hosaka M, Suda M, Sakai Y, Izumi T, Watanabe T, et al. (2004) Secretogranin
III binds to cholesterol in the secretory granule membrane as an adapter for
chromogranin A. J Biol Chem 279: 3627–3634.
60. Lechner T, Adlassnig C, Humpel C, Kaufmann WA, Maier H, et al. (2004)
Chromogranin peptides in Alzheimer’s disease. Exp Gerontol 39: 101–113.
61. Lassmann H, Weiler R, Fischer P, Bancher C, Jellinger K, et al. (1992)
Synaptic pathology in Alzheimer’s disease: immunological data for markers of
synaptic and large dense-core vesicles. Neuroscience 46: 1–8.
62. Eder U, Leitner B, Kirchmair R, Pohl P, Jobst KA, et al. (1998) Levels and
proteolytic processing of chromogranin A and B and secretogranin II in
cerebrospinal fluid in neurological diseases. J Neural Transm 105: 39–51.
Novel CSF Biomarkers for Early Alzheimer’s Disease
PLoS ONE | www.plosone.org 20 January 2011 | Volume 6 | Issue 1 | e1603263. Kaufmann WA, Barnas U, Humpel C, Nowakowski K, DeCol C, et al. (1998)
Synaptic loss reflected by secretoneurin-like immunoreactivity in the human
hippocampus in Alzheimer’s disease. Eur J Neurosci 10: 1084–1094.
64. Paco S, Pozas E, Aguado F (2010) Secretogranin III is an astrocyte granin that
is overexpressed in reactive glia. Cereb Cortex 20: 1386–1397.
65. Hosaka M, Watanabe T (2010) Secretogranin III: a bridge between core
hormone aggregates and the secretory granule membrane. Endocr J 57:
275–286.
66. Bozdagi O, Rich E, Tronel S, Sadahiro M, Patterson K, et al. (2008) The
neurotrophin-inducible gene Vgf regulates hippocampal function and behavior
through a brain-derived neurotrophic factor-dependent mechanism. J Neurosci
28: 9857–9869.
67. Ru ¨etschi U, Zetterberg H, Podust VN, Gottfries J, Li S, et al. (2005)
Identification of CSF biomarkers for frontotemporal dementia using SELDI-
TOF. Exp Neurol 196: 273–281.
68. Levi A, Ferri GL, Watson E, Possenti R, Salton SR (2004) Processing,
distribution, and function of VGF, a neuronal and endocrine peptide precursor.
Cell Mol Neurobiol 24: 517–533.
69. Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, et al.
(2003) Brain-derived neurotrophic factor-induced gene expression reveals novel
actions of VGF in hippocampal synaptic plasticity. J Neurosci 23:
10800–10808.
70. Steiner DF (1998) The proprotein convertases. Curr Opin Chem Biol 2(1):
31–39.
71. Zhu X, Wu K, Rife L, Cawley NX, Brown B, et al. (2005) Carboxypeptidase E
is required for normal synaptic transmission from photoreceptors to the inner
retina. J Neurochem 95: 1351–1362.
72. Hosaka M, Watanabe T, Sakai Y, Kato T, Takeuchi T (2005) Interaction
between secretogranin III and carboxypeptidase E facilitates prohormone
sorting within secretory granules. J Cell Sci 118: 4785–4795.
73. Park JJ, Koshimizu H, Loh YP (2009) Biogenesis and transport of secretory
granules to release site in neuroendocrine cells. J Mol Neurosci 37: 151–159.
74. Woronowicz A, Koshimizu H, Chang SY, Cawley NX, Hill JM, et al. (2008)
Absence of carboxypeptidase E leads to adult hippocampal neuronal
degeneration and memory deficits. Hippocampus 18: 1051–1063.
75. Woronowicz A, Cawley NX, Chang SY, Koshimizu H, Phillips AW, et al.
(2010) Carboxypeptidase E knockout mice exhibit abnormal dendritic
arborization and spine morphology in central nervous system neurons.
J Neurosci Res 88: 64–72.
76. Arun P, Moffett JR, Namboodiri AM (2009) Evidence for mitochondrial and
cytoplasmic N-acetylaspartate synthesis in SH-SY5Y neuroblastoma cells.
Neurochem Int 55: 219–225.
77. Schmidbaur JM, Kugler P, Horvath E (1990) Glutamate producing aspartate
aminotransferase in glutamatergic perforant path terminals of the rat
hippocampus. Cytochemical and lesion studies. Histochemistry 94: 427–433.
78. Wu ¨rdig S, Kugler P (1991) Histochemistry of glutamate metabolizing enzymes
in the rat cerebellar cortex. Neurosci Lett 130: 165–168.
79. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG (1997)
Diagnosis of Alzheimer’s disease with cerebrospinal fluid tau protein and
aspartate aminotransferase. Lancet 351: 63–64.
80. D’Aniello A, Fisher G, Migliaccio N, Cammisa G, D’Aniello E, et al. (2005)
Amino acids and transaminases activity in ventricular CSF and in brain of
normal and Alzheimer patients. Neurosci Lett 388: 49–53.
81. Jansen Steur E, Vermes I, de Vos RA (1998) Cerebrospinal-fluid tau protein
and aspartate aminotransferase in Parkinson’s disease. Lancet 351: 1105–1106.
82. Tapiola T, Lehtovirta M, Pirttila ¨ T, Alafuzoff I, Riekkinen P, et al. (1998)
Increased aspartate aminotransferase activity in cerebrospinal fluid and
Alzheimer’s disease. Lancet 352: 287.
83. Wright NT, Cannon BR, Zimmer DB, Weber DJ (2009) S100A1: Structure,
Function, and Therapeutic Potential. Curr Chem Biol 3: 138–145.
84. Liang D, Nunes-Tavares N, Xie HQ, Carvalho S, Bon S, et al. (2009) Protein
CutA undergoes an unusual transfer into the secretory pathway and affects the
folding, oligomerization, and secretion of acetylcholinesterase. J Biol Chem
284: 5195–5207.
85. Perrier AL, Cousin X, Boschetti N, Haas R, Chatel JM, et al. (2000) Two
distinct proteins are associated with tetrameric acetylcholinesterase on the cell
surface. J Biol Chem 275: 34260–34265.
86. Ablonczy Z, Prakasam A, Fant J, Fauq A, Crosson C, et al. (2009) Pigment
epithelium-derived factor maintains retinal pigment epithelium function by
inhibiting vascular endothelial growth factor-R2 signaling through gamma-
secretase. J Biol Chem 284: 30177–30186.
87. Castano E, Roher A, Esh C, Kokjohn T, Beach T (2006) Comparative
proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer’s
disease and non-demented elderly subjects. Neurol Res 28: 155–163.
88. Yamagishi S, Inagaki Y, Takeuchi M, Sasaki N (2004) Is pigment epithelium-
derived factor level in cerebrospinal fluid a promising biomarker for early
diagnosis of Alzheimer’s disease? Med Hypotheses 63: 115–117.
89. Takanohashi A, Yabe T, Schwartz JP (2005) Pigment epithelium-derived factor
induces the production of chemokines by rat microglia. Glia 51: 266–278.
90. Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, et al. (1999)
Pigment epithelium-derived factor (PEDF) protects motor neurons from
chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol
58: 719–728.
91. Davidsson P, Sjo ¨gren M, Andreasen N, Lindbjer M, Nilsson CL, et al. (2002)
Studies of the pathophysiological mechanisms in frontotemporal dementia by
proteome analysis of CSF proteins. Brain Res Mol Brain Res 109: 128–133.
92. Kuncl RW, Bilak MM, Bilak SR, Corse AM, Royal W, et al. (2002) Pigment
epithelium-derived factor is elevated in CSF of patients with amyotrophic
lateral sclerosis. J Neurochem 81: 178–184.
93. Yabe T, Sanagi T, Yamada H (2010) The neuroprotective role of PEDF:
implication for the therapy of neurological disorders. Curr Mol Med 10:
259–266.
94. Sanagi T, Yabe T, Yamada H (2005) The regulation of pro-inflammatory gene
expression induced by pigment epithelium-derived factor in rat cultured
microglial cells. Neurosci Lett 380: 105–110.
95. Sanagi T, Yabe T, Yamada H (2008) Gene transfer of PEDF attenuates
ischemic brain damage in the rat middle cerebral artery occlusion model.
J Neurochem 106: 1841–1854.
96. Pang IH, Zeng H, Fleenor DL, Clark AF (2007) Pigment epithelium-derived
factor protects retinal ganglion cells. BMC Neurosci 8: 11.
97. Perretti M, D’Acquisto F (2009) Annexin A1 and glucocorticoids as effectors of
the resolution of inflammation. Nat Rev Immunol 9: 62–70.
98. Lim LH, Pervaiz S (2007) Annexin 1: the new face of an old molecule. FASEB
Journal 21: 968–975.
99. Eberhard DA, Brown MD, VandenBerg SR (1994) Alterations of annexin
expression in pathological neuronal and glial reactions. Immunohistochemical
localization of annexins I, II (p36 and p11 subunits), IV, and VI in the human
hippocampus. Am J Pathol 145: 640–649.
100. Misasi R, Hozumi I, Inuzuka T, Capozzi A, Mattei V, et al. (2009)
Biochemistry and neurobiology of prosaposin: a potential therapeutic neuro-
effector. Cent Nerv Syst Agents Med Chem 9: 119–131.
101. Ochiai T, Takenaka Y, Kuramoto Y, Kasuya M, Fukuda K, et al. (2008)
Molecular mechanism for neuro-protective effect of prosaposin against
oxidative stress: its regulation of dimeric transcription factor formation.
Biochim Biophys Acta 1780: 1441–1447.
102. Sikora J, Harzer K, Elleder M (2007) Neurolysosomal pathology in human
prosaposin deficiency suggests essential neurotrophic function of prosaposin.
Acta Neuropathol 113: 163–175.
103. O’Brien JS, Carson GS, Seo HC, Hiraiwa M, Kishimoto Y (1994)
Identification of prosaposin as a neurotrophic factor. Proc Natl Acad
Sci U S A 91: 9593–9596.
104. Li L, Hung AC, Porter AG (2008) Secretogranin II: a key AP-1-regulated
protein that mediates neuronal differentiation and protection from nitric oxide-
induced apoptosis of neuroblastoma cells. Cell Death Differ 15: 879–888.
105. Shyu WC, Lin SZ, Chiang MF, Chen DC, Su CY, et al. (2008) Secretoneurin
promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway
in murine models of stroke. J Clin Invest 118: 133–148.
106. Gasser MC, Berti I, Hauser KF, Fischer-Colbrie R, Saria A (2003)
Secretoneurin promotes pertussis toxin-sensitive neurite outgrowth in cerebel-
lar granule cells. J Neurochem 85: 662–669.
107. Hipkiss AR (2007) Could carnosine or related structures suppress Alzheimer’s
disease? J Alzheimers Dis 11: 229–240.
108. Guiotto A, Calderan A, Ruzza P, Borin G (2005) Carnosine and carnosine-
related antioxidants: a review. Curr Med Chem 12: 2293–2315.
109. Yin GN, Lee HW, Cho JY, Suk K (2009) Neuronal pentraxin receptor in
cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
Brain Res 1265: 158–170.
110. Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, et al. (2003)
Sequence identification and characterization of human carnosinase and a
closely related non-specific dipeptidase. J Biol Chem 278: 6521–6531.
111. Balion CM, Benson C, Raina PS, Papaioannou A, Patterson C, et al. (2007)
Brain type carnosinase in dementia: a pilot study. BMC Neurol 7: 38.
112. Zelko IN, Mariani TJ, Folz RJ (2002) Superoxide dismutase multigene family: a
comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD
(SOD3) gene structures, evolution, and expression. Free Radic Biol Med 33:
337–349.
113. Folz RJ, Crapo JD (1994) Extracellular superoxide dismutase (SOD3): tissue-
specific expression, genomic characterization, and computer-assisted sequence
analysis of the human EC SOD gene. Genomics 22: 162–171.
114. Levin ED (2005) Extracellular superoxide dismutase (EC-SOD) quenches free
radicals and attenuates age-related cognitive decline: opportunities for novel
drug development in aging. Curr Alzheimer Res 2: 191–196.
115. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, et al. (1997) Caspase-
3-generated fragment of gelsolin: effector of morphological change in apoptosis.
Science 278: 294–298.
116. Nag S, Ma Q, Wang H, Chumnarnsilpa S, Lee WL, et al. (2009) Ca2+ binding
by domain 2 plays a critical role in the activation and stabilization of gelsolin.
Proc Natl Acad Sci U S A 106: 13713–13718.
117. Chauhan VP, Ray I, Chauhan A, Wisniewski HM (1999) Binding of gelsolin, a
secretory protein, to amyloid beta-protein. Biochem Biophys Res Commun
258: 241–246.
118. Ray I, Chauhan A, Wegiel J, Chauhan VP (2000) Gelsolin inhibits the
fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils.
Brain Res 853: 344–351.
119. Ji L, Chauhan A, Wegiel J, Essa MM, Chauhan V (2009) Gelsolin is
proteolytically cleaved in the brains of individuals with Alzheimer’s disease.
J Alz Dis 18: 105–111.
Novel CSF Biomarkers for Early Alzheimer’s Disease
PLoS ONE | www.plosone.org 21 January 2011 | Volume 6 | Issue 1 | e16032120. Slee EA, Adrain C, Martin SJ (2001) Executioner caspase-3, -6, and -7 perform
distinct, non-redundant roles during the demolition phase of apoptosis. J Biol
Chem 276: 7320–7326.
121. Antequera D, Vargas T, Ugalde C, Spuch C, Molina JA, et al. (2009)
Cytoplasmic gelsolin increases mitochondrial activity and reduces Abeta
burden in a mouse model of Alzheimer’s disease. Neurobiol Dis 36: 42–50.
122. Owen D, Lowe PN, Nietlispach D, Brosnan CE, Chirgadze DY, et al. (2003)
Molecular dissection of the interaction between the small G proteins Rac1 and
RhoA and protein kinase C-related kinase 1 (PRK1). J Biol Chem 278:
50578–50587.
123. Palmer RH, Parker PJ (1995) Expression, purification and characterization of
the ubiquitous protein kinase C-related kinase 1. Biochem J 309: 315–320.
124. Okii N, Amano T, Seki T, Matsubayashi H, Mukai H, et al. (2007)
Fragmentation of protein kinase N (PKN) in the hydrocephalic rat brain. Acta
Histochem Cytochem 40: 113–121.
125. Takahashi M, Mukai H, Toshimori M, Miyamoto M, Ono Y (1998) Proteolytic
activation of PKN by caspase-3 or related protease during apoptosis. Proc Natl
Acad Sci U S A 95: 11566–11571.
126. Ueyama T, Ren Y, Sakai N, Takahashi M, Ono Y, et al. (2001) Generation of
a constitutively active fragment of PKN in microglia/macrophages after middle
cerebral artery occlusion in rats. J Neurochem 79: 903–913.
127. Henion TR, Raitcheva D, Grosholz R, Biellmann F, Skarnes WC, et al. (2005)
Beta1,3-N-acetylglucosaminyltransferase 1 glycosylation is required for axon
pathfinding by olfactory sensory neurons. J Neurosci 25: 1894–1903.
128. Puche AC, Bartlett PF, Key B (1997) Substrate-bound carbohydrates stimulate
signal transduction and neurite outgrowth in an olfactory neuron cell line.
Neuroreport 8: 3183–3188.
129. Svichar N, Esquenazi S, Waheed A, Sly WS, Chesler M (2006) Functional
demonstration of surface carbonic anhydrase IV activity on rat astrocytes. Glia
53: 241–247.
130. Svichar N, Waheed A, Sly WS, Hennings JC, Hubner CA, et al. (2009) The
Carbonic Anhydrases CA4 and CA14 Both Enhance AE3-Mediated Cl–
HCO3 Exchange in Hippocampal Neurons. J Neurosci 29: 3252–3258.
131. Shah GN, Ulmasov B, Waheed A, Becker T, Makani S, et al. (2005) Carbonic
anhydrase IV and XIV knockout mice: roles of the respective carbonic
anhydrases in buffering the extracellular space in brain. Proc Natl Acad
Sci U S A 102: 16771–16776.
132. Benfenati F, Ferrari R, Onofri F, Arcuri C, Giambanco I, et al. (2004) S100A1
codistributes with synapsin I in discrete brain areas and inhibits the F-actin-
bundling activity of synapsin I. J Neurochem 89: 1260–1270.
133. Redondo RL, Okuno H, Spooner PA, Frenguelli BG, Bito H, et al. (2010)
Synaptic tagging and capture: differential role of distinct calcium/calmodulin
kinases in protein synthesis-dependent long-term potentiation. J Neurosci 30:
4981–4989.
134. Zhong L, Cherry T, Bies CE, Florence MA, Gerges NZ (2009) Neurogranin
enhances synaptic strength through its interaction with calmodulin. EMBO J
28: 3027–3039.
135. Liu X, Yang PS, Yang W, Yue DT (2010) Enzyme-inhibitor-like tuning of
Ca(2+) channel connectivity with calmodulin. Nature 463: 968–972.
136. Supnet C, Bezprozvanny I (2010) Neuronal calcium signaling, mitochondrial
dysfunction, and Alzheimer’s disease. J Alzheimers Dis 20(Suppl 2): S487–498.
137. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, et al. (2010) YKL-
40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer’s Disease.
Biol Psychiatry 68: 903–12.
138. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, et al. (2006)
Expression profiles for macrophage alternative activation genes in AD and in
mouse models of AD. J Neuroinflammation 3: 27.
139. Kolson DL (2008) YKL-40: a candidate biomarker for simian immunodefi-
ciency virus and human immunodeficiency virus encephalitis? Am J Pathol
173: 25–29.
140. Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, et al. (2008)
YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates
the biological activity of basic fibroblast growth factor. Am J Pathol 173:
130–143.
141. Ostergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD (2002) YKL-40
is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin
Diagn Lab Immunol 9: 598–604.
142. Kaynar MY, Tanriverdi T, Kafadar AM, Kacira T, Yurdakul F, et al. (2005)
YKL-40 levels in the cerebrospinal fluid and serum of patients with aneurysmal
subarachnoid hemorrhage: preliminary results. J Clin Neurosci 12: 754–757.
143. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE (2005)
Regulation of YKL-40 expression during genotoxic or microenvironmental
stress in human glioblastoma cells. Cancer Sci 96: 183–190.
144. Hakala BE, White C, Recklies AD (1993) Human cartilage gp-39, a major
secretory product of articular chondrocytes and synovial cells, is a mammalian
member of a chitinase protein family. J Biol Chem 268: 25803–25810.
145. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, et al. (2007) A chitinase-
like protein in the lung and circulation of patients with severe asthma.
N Engl J Med 357: 2016–2027.
146. Ling H, Recklies AD (2004) The chitinase 3-like protein human cartilage
glycoprotein 39 inhibits cellular responses to the inflammatory cytokines
interleukin-1 and tumour necrosis factor-alpha. Biochem J 380: 651–659.
147. Le ´tuve ´ S, Kozhich A, Arouche N, Grandsaigne M, Reed J, et al. (2008) YKL-
40 is elevated in patients with chronic obstructive pulmonary disease and
activates alveolar macrophages. J Immunol 181: 5167–5173.
148. Roberts ES, Zandonatti MA, Watry DD, Madden LJ, Henriksen SJ, et al.
(2003) Induction of pathogenic sets of genes in macrophages and neurons in
NeuroAIDS. Am J Pathol 162: 2041–2057.
149. Choi-Miura NH, Takahashi K, Yoda M, Saito K, Hori M, et al. (2000) The
novel acute phase protein, IHRP, inhibits actin polymerization and
phagocytosis of polymorphonuclear cells. Inflamm Res 49: 305–310.
150. Choi-Miura NH (2004) Novel human plasma proteins, IHRP (acute phase
protein) and PHBP (serine protease), which bind to glycosaminoglycans. Curr
Med Chem Cardiovasc Hematol Agents 2: 239–248.
151. Akiyama H, Kawamata T, Dedhar S, McGeer PL (1991) Immunohistochem-
ical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer
brain tissue. J Neuroimmunol 32: 19–28.
152. McGeer PL, Kawamata T, Walker DG (1992) Distribution of clusterin in
Alzheimer brain tissue. Brain Res 579: 337–341.
153. Shin TM, Isas JM, Hsieh CL, Kayed R, Glabe CG, et al. (2008) Formation of
soluble amyloid oligomers and amyloid fibrils by the multifunctional protein
vitronectin. Mol Neurodegener 3: 16.
154. Milner R, Campbell IL (2003) The extracellular matrix and cytokines regulate
microglial integrin expression and activation. J Immunol 170: 3850–3858.
155. Milner R, Crocker SJ, Hung S, Wang X, Frausto RF, et al. (2007) Fibronectin-
and vitronectin-induced microglial activation and matrix metalloproteinase-9
expression is mediated by integrins alpha5beta1 and alphavbeta5. J Immunol
178: 8158–8167.
156. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-
wide association study identifies variants at CLU and CR1 associated with
Alzheimer’s disease. Nat Genet 41: 1094–1099.
157. Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, et al. (2005)
Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc
Disord 19: 55–66.
158. Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, et al.
(2000) Temporal accrual of complement proteins in amyloid plaques in Down’s
syndrome with Alzheimer’s disease. Am J Pathol 156: 489–499.
159. Loeffler DA, Camp DM, Schonberger MB, Singer DJ, LeWitt PA (2004) Early
complement activation increases in the brain in some aged normal subjects.
Neurobiol Aging 25: 1001–1007.
160. Finehout EJ, Franck Z, Lee KH (2005) Complement protein isoforms in CSF
as possible biomarkers for neurogenerative disease. Dis Markers 21: 93–101.
161. Masaki T, Matsumoto M, Nakanishi I, Yasuda R, Seya T (1992) Factor I-
dependent inactivation of human complement C4b of the classical pathway by
C3b/C4b receptor (CR1, CD35) and membrane cofactor protein (MCP,
CD46). J Biochem 111: 573–578.
162. Puchades M, Hansson S, Nilsson C, Andreasen N, Blennow K, et al. (2003)
Proteomic studies of potential cerebrospinal fluid protein markers for
Alzheimer’s disease. Mol Brain Res 118: 140–146.
163. Bergamaschini L, Donarini C, Gobbo G, Parnetti L, Gallai V (2001) Activation
of complement and contact system in Alzheimer’s disease. Mech Ageing Dev
122: 1971–1983.
164. Murphy BF, Saunders JR, O’Bryan MK, Kirszbaum L, Walker ID, et al.
(1989) SP-40 is an inhibitor of C5b-6-initiated haemolysis. Int Immunol 1:
551–554.
165. Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg HJ, et al. (2001)
Characterization of four lipoprotein classes in human cerebrospinal fluid.
J Lipid Res 42: 1143–1151.
166. Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ (1996) Brain expression
of apolipoproteins E, J, and A-I in Alzheimer’s disease. J Neurochem 66:
2429–2435.
167. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009)
Genome-wide association study identifies variants at CLU and PICALM
associated with Alzheimer’s disease. Nat Genet 41: 1088–1093.
168. Perarnau B, Siegrist CA, Gillet A, Vincent C, Kimura S, et al. (1990) Beta 2-
microglobulin restriction of antigen presentation. Nature 346: 751–754.
169. Vitiello A, Potter TA, Sherman LA (1990) The role of beta 2-microglobulin in
peptide binding by class I molecules. Science 250: 1423–1426.
170. Berggard I, Bearn AG (1968) Isolation and properties of a low molecular
weight beta-2-globulin occurring in human biological fluids. J Biol Chem 243:
4095–4103.
171. Nissen MH, Roepstorff P, Thim L, Dunbar B, Fothergill JE (1990) Limited
proteolysis of beta 2-microglobulin at Lys-58 by complement component C1s.
Eur J Biochem 189: 423–429.
172. Lob HE, Marvar PJ, Guzik TJ, Sharma S, McCann LA, et al. Induction of
hypertension and peripheral inflammation by reduction of extracellular
superoxide dismutase in the central nervous system. Hypertension 55:
277–283, 276p following 283.
173. Hansson SF, Andre ´asson U, Wall M, Skoog I, Andreasen N, et al. (2009)
Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from
Alzheimer’s disease patients. J Alzheimers Dis 16: 389–397.
174. Kanekiyo T, Ban T, Aritake K, Huang ZL, Qu WM, et al. (2007) Lipocalin-
type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in
human cerebrospinal fluid. Proc Natl Acad Sci U S A 104: 6412–6417.
Novel CSF Biomarkers for Early Alzheimer’s Disease
PLoS ONE | www.plosone.org 22 January 2011 | Volume 6 | Issue 1 | e16032175. Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, et al. (2008) An aberrant
protein complex in CSF as a biomarker of Alzheimer disease. Neurology 70:
2212–2218.
176. Paula-Lima AC, Tricerri MA, Brito-Moreira J, Bomfim TR, Oliveira FF, et al.
(2009) Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-
induced neurotoxicity. Int J Biochem Cell Biol 41: 1361–1370.
177. Wisniewski T, Golabek AA, Kida E, Wisniewski KE, Frangione B (1995)
Conformational mimicry in Alzheimer’s disease. Role of apolipoproteins in
amyloidogenesis. Am J Pathol 147: 238–244.
178. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in
Alzheimer’s disease. Neuron 63: 287–303.
179. Biroccio A, Del Boccio P, Panella M, Bernardini S, Di Ilio C, et al. (2006)
Differential post-translational modifications of transthyretin in Alzheimer’s
disease: a study of the cerebral spinal fluid. Proteomics 6: 2305–2313.
180. Wati H, Kawarabayashi T, Matsubara E, Kasai A, Hirasawa T, et al. (2009)
Transthyretin accelerates vascular Abeta deposition in a mouse model of
Alzheimer’s disease. Brain Pathol 19: 48–57.
181. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, et al. (2008) Transthyretin
protects Alzheimer’s mice from the behavioral and biochemical effects of Abeta
toxicity. Proc Natl Acad Sci U S A 105: 2681–2686.
182. Buxbaum JN, Reixach N (2009) Transthyretin: the servant of many masters.
Cell Mol Life Sci 66: 3095–3101.
183. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I (2008) Transthyretin
protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a
mechanism sensitive to the Kunitz protease inhibitor. PLoS One 3: e2899.
184. Choi SH, Leight SN, Lee VM, Li T, Wong PC, et al. (2007) Accelerated Abeta
deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR
(transthyretin). J Neurosci 27: 7006–7010.
185. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, et al. (2007)
Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 39: 1437–1439.
186. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, et al. (2008) Cystatin C-cathepsin
B axis regulates amyloid beta levels and associated neuronal deficits in an
animal model of Alzheimer’s disease. Neuron 60: 247–257.
187. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, et al. (2007) Cystatin C
inhibits amyloid-beta deposition in Alzheimer’s disease mouse models. Nat
Genet 39: 1440–1442.
188. Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A,
Grubb A (2007) Cystatin C reduces the in vitro formation of soluble Abeta1-
42 oligomers and protofibrils. Scand J Clin Lab Invest 67: 179–190.
189. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, et al. (1993)
Cytokine indices in Alzheimer’s temporal cortex: no changes in mature IL-1
beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha
2-macroglobulin and C-reactive protein. Brain Res 629: 245–252.
190. Narita M, Holtzman DM, Schwartz AL, Bu G (1997) a2-Macroglobulin
complexes with and mediates the endocytosis of b-amyloid peptide via cell surface
low-density lipoprotein receptor-related protein. J Neurochem 69: 1904–1911.
191. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, et al. (2006)
Proteome-based plasma biomarkersforAlzheimer’sdisease.Brain129: 3042–3050.
192. Kovacs DM (2000) alpha2-macroglobulin in late-onset Alzheimer’s disease.
Exp Gerontol 35: 473–479.
193. French K, Yerbury JJ, Wilson MR (2008) Protease activation of alpha2-
macroglobulin modulates a chaperone-like action with broad specificity.
Biochemistry 47: 1176–1185.
194. Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, et al. (1998)
Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril
formation. Proc Natl Acad Sci U S A 95: 3275–3280.
195. Abraham C, Selkoe D, Potter H (1988) Immunochemical identification of the
serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid
deposits of Alzheimer’s disease. Cell 52: 487–501.
196. Harigaya Y, Shoji M, Nakamura T, Matsubara E, Hosoda K, et al. (1995)
Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with
late onset Alzheimer’s disease. Intern Med 34: 481–484.
197. Abraham CR, McGraw WT, Slot F, Yamin R (2000) Alpha 1-antic-
hymotrypsin inhibits A beta degradation in vitro and in vivo. Ann N Y Acad
Sci 920: 245–248.
198. DeKosky S, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, et al. (2003)
Plasma and cerebrospinal fluid 1-Antichymotrypsin levels in Alzheimer’s
disease: correlation with cognitive impairnent. Ann Neurol 53: 81–90.
199. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, et al. (2007)
Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies.
Neurology 69: 1569–1579.
200. Vukovic J, Marmorstein LY, McLaughlin PJ, Sasaki T, Plant GW, et al. (2009)
Lack of fibulin-3 alters regenerative tissue responses in the primary olfactory
pathway. Matrix Biol 28: 406–415.
201. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS (2009) Fibulin-3 is
uniquely upregulated in malignant gliomas and promotes tumor cell motility
and invasion. Mol Cancer Res 7: 1756–1770.
202. Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B (2004) Tissue
inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial
growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1).
Implications for macular degenerations. J Biol Chem 279: 30469–30473.
203. Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, et al. (2005)
APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann
Neurol 58: 436–441.
204. Montine TJ, Montine KS, Swift LL (1997) Central nervous system lipoproteins
in Alzheimer’s disease. Am J Path 151: 1571–1575.
205. Gunzburg MJ, Perugini MA, Howlett GJ (2007) Structural basis for the
recognition and cross-linking of amyloid fibrils by human apolipoprotein E.
J Biol Chem 282: 35831–35841.
206. Sun Y, Shi J, Zhang S, Tang M, Han H, et al. (2005) The APOC3 SstI
polymorphism is weakly associated with sporadic Alzheimer’s disease in a
Chinese population. Neurosci Lett 380: 219–222.
207. Houlden H, Crook R, Duff K, Hutton M, Collinge J, et al. (1995)
Apolipoprotein E alleles but neither apolipoprotein B nor apolipoprotein AI/
CIII alleles are associated with late onset, familial Alzheimer’s disease. Neurosci
Lett 188: 202–204.
208. Pan S, Rush J, Peskind ER, Galasko D, Chung K, et al. (2008) Application of
targeted quantitative proteomics analysis in human cerebrospinal fluid using a
liquid chromatography matrix-assisted laser desorption/ionization time-of-
flight tandem mass spectrometer (LC MALDI TOF/TOF) platform.
J Proteome Res 7: 720–730.
209. Katzav A, Faust-Socher A, Kvapil F, Michaelson DM, Blank M, et al. (2009)
Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer
disease model on a female background. Neurobiol Aging.
210. Zimmer DB, Chaplin J, Baldwin A, Rast M (2005) S100-mediated signal
transduction in the nervous system and neurological diseases. Cell Mol Biol
(Noisy-le-grand) 51: 201–214.
211. Loeffler DA, LeWitt PA, Juneau PL, Sima AA, Nguyen HU, et al. (1996)
Increased regional brain concentrations of ceruloplasmin in neurodegenerative
disorders. Brain Res 738: 265–274.
212. Castellani RJ, Smith MA, Nunomura A, Harris PL, Perry G (1999) Is increased
redox-active iron in Alzheimer disease a failure of the copper-binding protein
ceruloplasmin? Free Radic Biol Med 26: 1508–1512.
213. Kaneko K, Yoshida K, Arima K, Ohara S, Miyajima H, et al. (2002) Astrocytic
deformity and globular structures are characteristic of the brains of patients
with aceruloplasminemia. J Neuropathol Exp Neurol 61: 1069–1077.
214. Kessler H, Pajonk FG, Meisser P, Schneider-Axmann T, Hoffmann KH, et al.
(2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma
copper and ceruloplasmin in patients with Alzheimer’s disease. J Neural
Transm 113: 1763–1769.
215. Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, et al. (2008) Features
of ceruloplasmin in the cerebrospinal fluid of Alzheimer’s disease patients.
Biometals 21: 367–372.
216. Squitti R, Quattrocchi CC, Salustri C, Rossini PM (2008) Ceruloplasmin
fragmentation is implicated in ‘free’ copper deregulation of Alzheimer’s disease.
Prion 2: 23–27.
217. Squitti R, Bressi F, Pasqualetti P, Bonomini C, Ghidoni R, et al. (2009)
Longitudinal prognostic value of serum ‘‘free’’ copper in patients with
Alzheimer disease. Neurology 72: 50–55.
218. Okada M, Hatakeyama T, Itoh H, Tokuta N, Tokumitsu H, et al. (2004)
S100A1 is a novel molecular chaperone and a member of the Hsp70/Hsp90
multichaperone complex. J Biol Chem 279: 4221–4233.
219. Lein ES, Callaway EM, Albright TD, Gage FH (2005) Redefining the
boundaries of the hippocampal CA2 subfield in the mouse using gene
expression and 3-dimensional reconstruction. J Comp Neurol 485: 1–10.
220. Hosokawa N, You Z, Tremblay LO, Nagata K, Herscovics A (2007)
Stimulation of ERAD of misfolded null Hong Kong alpha1-antitrypsin by
Golgi alpha1,2-mannosidases. Biochem Biophys Res Commun 362: 626–632.
221. Schweden J, Bause E (1989) Characterization of trimming Man9-mannosidase
from pig liver. Purification of a catalytically active fragment and evidence for the
transmembrane nature of the intact 65 kDa enzyme. Biochem J 264: 347–355.
222. Kehoe PG, Miners S, Love S (2009) Angiotensins in Alzheimer’s disease -
friend or foe? Trends Neurosci 32: 619–628.
223. Blennow K, Davidsson P, Wallin A, Ekman R (2004) Chromogranin A in
cerebrospinal fluid: a biochemical marker for synaptic degeneration in
Alzheimer’s disease? Dementia 6: 306–11.
224. Massaro AR, De Pascalis D, Carnevale A, Carbone G (2009) The neural cell
adhesion molecule (NCAM) present in the cerebrospinal fluid of multiple
sclerosis patients is unsialylated. Eur Rev Med Pharmacol Sci 13: 397–9.
225. Todaro L, Puricelli L, Gioseffi H, Pallotta MG, Lastiri J, et al. (2004) Neural
cell adhesion molecule in human serum. Increased levels in dementia of the
Alzheimer type. Neurobiol Dis 15: 387–393.
226. Kapaki E, Paraskevas GP, Papageorgiou SG, Bonakis A, Kalfakis N, et al.
(2008) Diagnostic value of CSF biomarker profile in frontotemporal lobar
degeneration. Alzheimer Dis Assoc Disord 22: 47–53.
227. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, et al. (2008) CSF
biomarkers in frontotemporal lobar degeneration with known pathology.
Neurology 70: 1827–1835.
228. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, et al. (2008) Direct
quantification of CSF alpha-synuclein by ELISA and first cross-sectional study
in patients with neurodegeneration. Exp Neurol 213: 315–325.
229. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, et al.
(2009) A gamma-secretase inhibitor decreases amyloid-beta production in the
central nervous system. Ann Neurol 66: 48–54.
230. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, et al. (2006)
Association between CSF biomarkers and incipient Alzheimer’s disease in
patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5:
228–234.
Novel CSF Biomarkers for Early Alzheimer’s Disease
PLoS ONE | www.plosone.org 23 January 2011 | Volume 6 | Issue 1 | e16032